Signed By [CONTACT_232389]/Time (UTC)APPROVALSCONFIDENTIAL  
DOCUMENT/RECORD  
 
This document/record is electronically controlled; printed copi[INVESTIGATOR_42546]. 
System of Record: Regulatory Affairs Domain  
Document Name [CONTACT_232428]
05/03/2018 16:25:36
1.0
Document Approver
05/02/2018 13:57:27
Lande, Jeff
REVAMP Study Clean Version 3. 27APR2018 docx.pdf
Document Approver
Wallace, Kristie
05/03/2018 16:07:20
Chesness, Dana
05/01/2018 16:56:19
Berg, Melinda, RN
Jackson, Troy
Document Approver
Document Author
05/01/2018 17:51:00
Hannon, Cole
05/03/2018 15:40:01
Randall, Taryn
Heim, Jennifer
05/01/2018 16:59:14
05/01/2018 17:25:07
Document Approver
05/03/2018 17:21:02
Pi[INVESTIGATOR_26672], Karen
Document Approver
REVAMP Study Clean Version 3. 27APR2018 docx.pdf

 056-F275 , Version 2.0  
Global Form  Clinical Investigation Plan Template  
 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 
 
  
 
Clinical Investigation Plan  
Clinical Investigation Plan/Study Title  REVAMP  Study  (REmodeling the Left Ventricle 
with Atrial Modulated Pacing)  
Sponsor/Local Sponsor  Medtronic, Inc.  
Cardiac Rhythm and Heart Failure Clinical 
Research  
[ADDRESS_567248] NE  
Mounds View, MN [ZIP_CODE] U.S.A.  
[PHONE_2905] 
 
Document Version  3.[ADDRESS_567249] information w ill be sent to sites as needed.  
Table 1: Study Sponsor Contact [CONTACT_446140] C ontacts  
Clinical Study Leader  
 
Andrea De[COMPANY_002], Principal Clinical Research Specialist  
Direct Phone: (+1 -[PHONE_9319] 
[EMAIL_8541]  
Study Monitors and C ontacts  
Monitoring Leader  
 
Taryn Randall, Clinical Monitoring Manager  
Direct Phone: (+1 -763) [ADDRESS_567250] Fax: (+1 -651) 367 -0759 
[EMAIL_8542]  
Sponsor’s Medical Expert  
[INVESTIGATOR_446177], VP Medical Affairs, CRHF  
 
[ADDRESS_567251] N.E., MVC42  
Mounds View, MN [ZIP_CODE]  
[LOCATION_002]  
Phone: (+1 -763) 526 -5705 
[EMAIL_8543]  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 3 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 CROs/Core Laboratories  
This information may be subject to change during the course of the clinical study. Periodic updates to 
study contact [CONTACT_446141].  
Table 2: CRO and Core Laboratory Information  
Contact [CONTACT_446142]  
[ADDRESS_567252] Phone: (201) [ADDRESS_567253] Fax: ([PHONE_2908] Review of electronic case report forms and 
management of discrepancies  
Echocardiography Core Laboratory  
 
The Ohio State University  
[ADDRESS_567254], Columbus, Ohio [ZIP_CODE]  Review of study echocardiograms  
Blood Core Laboratory  
 
ACM Global Central Laboratory  
160 Elmgrove Park | [COMPANY_002]ster, NY [ZIP_CODE]  
 Review of blood samples  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 4 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 1.   Version History  
Version  Summary of Changes  Author(s)/Title  
1.0 • Not Applicable, New Document   Nancy Bennett , Prin. Field Clinical 
Site Specialist  
Jeff Lande, Prin. Statistician  
Teri Whitman, Sr. Prinicipal 
Scientist  
Matt Zmijewski, Distinguished 
Field Clinical Engineer  
 
2.0 • Refer to Appendix G  Table [ADDRESS_567255]  
 
3.0 • Refer to Appendix G Table [ADDRESS_567256]  ................................ ................................ ................................ ...................  2 
CROs/Core Laboratories  ................................ ................................ ................................ ..... 3 
1.   V ersion History  ................................ ................................ ................................ ...............  4 
2.   Investigator Statement  ................................ ................................ ................................ .........  4 
Table of Contents  ................................ ................................ ................................ .................  5 
3.   Glossary  ................................ ................................ ................................ ..........................  9 
4.   Synopsis  ................................ ................................ ................................ ........................  12 
5.   Introduction  ................................ ................................ ................................ ..................  17 
5.1.   Background  ................................ ................................ ................................ .........................  17 
5.2.   Pur pose  ................................ ................................ ................................ ...............................  19 
6.    Objectives and Endpoints  ................................ ................................ ............................  20 
6.1   Objectives  ................................ ................................ ................................ ................................ .. 20 
6.1.1.  Primary Objectives  ................................ ................................ ................................ ................................ ....... 20 
6.1.2.  Ancillary/Exploratory Objectives  ................................ ................................ ................................ ..............  [ADDRESS_567257] Consent  ................................ ................................ ................................ ......................  32 
10.8.   Enrollment  ................................ ................................ ................................ ..............................  34 
10.9.   Baseline Visit  ................................ ................................ ................................ ..........................  34 
10.9.1.   Programming Recommendations at Baseline  ................................ ................................ .......................  35 
10.10.   Scheduled Follow -Up Phone Calls  ................................ ................................ .......................  36 
10.11.   Randomization (4 Week Follow -Up) ................................ ................................ ....................  36 
10.11.1.   Blinding  ................................ ................................ ................................ ................................ .....................  37 
10.11.2.   Programming Recommendations at 4 Week Follow -Up ................................ ................................ .. 37 
10.12.   8 Week Follow -Up ................................ ................................ ................................ .................  38 
10.12.1.   Programming Recommendations  ................................ ................................ ................................ .........  39 
10.13.   Unscheduled Follow -Up Visits  ................................ ................................ .............................  40 
10.14.   12 Week Visit (Study Exit)  ................................ ................................ ................................ .... [ADDRESS_567258] chooses to exit (i.e. revokes informed consent)  ................................ ................................ ... [ADDRESS_567259]  ................................ ................................ ................................ ............  42 
10.16.   Device Interrogation / Save -to-Media  ................................ ................................ ..................  42 
10.17.   System Modification  ................................ ................................ ................................ .............  42 
10.18.   Deviation Handling  ................................ ................................ ................................ ..............  42 
10.19.   Assessment of Safety  ................................ ................................ ................................ .............  43 
10.20.   Assessment of Efficacy  ................................ ................................ ................................ .........  43 
10.21.   Recording Data  ................................ ................................ ................................ .....................  44 
11.   Risks and Benefits  ................................ ................................ ................................ ............  44 
11.1.   Potential Risks  ................................ ................................ ................................ ........................  44 
11.2.   Risk Minimization  ................................ ................................ ................................ ..................  46 
11.3.   Potential Benefits  ................................ ................................ ................................ ....................  46 
11.4.   Risk -Benefit Rationale  ................................ ................................ ................................ ............  46 
12.   Adverse Event Assessments  ................................ ................................ .............................  46 
12.1.   Adverse Events  ................................ ................................ ................................ .......................  47 
12.2.   Device Deficiencies  ................................ ................................ ................................ ................  47 
12.3.   Processing Updates and Resolution ................................ ................................ .......................  47 
12.4.   Definitions/Classifications  ................................ ................................ ................................ .... [ADDRESS_567260] Complaint Reporting  ................................ ................................ ................................  52 
13.   Data Review Committees  ................................ ................................ ................................ . 52 
13.1.   Echocardiography Core Laboratory  ................................ ................................ .......................  52 
13.2.   Blood Core Laboratory  ................................ ................................ ................................ ...........  52 
14.   Statistical Design and Methods  ................................ ................................ .......................  53 
14.1.   Endpoint Definitions  ................................ ................................ ................................ ..............  56 
14.1.1.   Ancillary Safety and Tolerability Endpoint  ................................ ................................ ...........................  56 
14.1.2.   Ancillary Safety Endpoint – NT-proBNP, troponin, LVEF  ................................ ..............................  56 
14.1.3.   Ancillary Safety Endpoint – Adverse Events  ................................ ................................ ........................  57 
14.1.4.   Ancillary Efficacy Endpoint - Quality of Life ................................ ................................ .......................  58 
14.1.5.   Ancillary Efficacy Endpoint - Mobility and Activity  ................................ ................................ ...........  59 
14.1.6.   Ancillary Efficacy Endpoin t – Echo Measurements  ................................ ................................ ...........  61 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 7 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 14.1.7.   Ancillary Efficacy Endpoint – Collagen Degradation Biomarker Measurements  ..........................  62 
14.1.8.   Ancillary Efficacy Endpoint – Sustained effects of elevated night pacing  ................................ ....... 63 
15.   Ethics  ................................ ................................ ................................ ................................  63 
15.1.   Statement(s) of Compliance  ................................ ................................ ................................ ... [ADDRESS_567261] Access to Source Data/Documents  ................................ ................................ ............  65 
16.4.   Confidentiality  ................................ ................................ ................................ ........................  65 
16.5.   CIP Amendments  ................................ ................................ ................................ ...................  65 
16.6.   Warranty/Insurance Information  ................................ ................................ ...........................  [ADDRESS_567262] Retention  ................................ ................................ ................................ ....................  65 
16.7.1.   Investigator Records  ................................ ................................ ................................ ................................ . 65 
16.7.2.   Investigator Reports  ................................ ................................ ................................ ................................ .. 66 
16.7.3.   Sponsor Records  ................................ ................................ ................................ ................................ ........ 67 
16.7.4.   Sponsor Reports  ................................ ................................ ................................ ................................ ........ 67 
16.8.   Publication and Use of Information  ................................ ................................ .......................  68 
16.8.1.   Publication Committee  ................................ ................................ ................................ .............................  68 
16.8.2.   Management of Primary, Secondary, and Ancillary Publications  ................................ ......................  69 
16.8.3.    Criteria for Determining Authorship  ................................ ................................ ................................ ..... 69 
16.8.4.   Transparency  ................................ ................................ ................................ ................................ ..............  69 
16.9.   Suspension or Early Termination  ................................ ................................ ...........................  70 
16.9.1.   Planned Study Closure  ................................ ................................ ................................ ..............................  70 
16.9.2.   Early Termination or Suspension  ................................ ................................ ................................ ...........  70 
16.9.3.   Procedures for Termination or Suspension  ................................ ................................ ..........................  71 
17.   Appendices  ................................ ................................ ................................ .......................  72 
18.   References  ................................ ................................ ................................ ........................  89 
 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 8 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 1: Study Sponsor Contact [CONTACT_7171]  ................................ ................................ ................................  2 
Table 2: CRO and Core Laboratory Information  ................................ ................................ ...........................  3 
Table 3: Steering Committee Members  ................................ ................................ ................................ ...... 23 
Table 4: Study Procedures  ................................ ................................ ................................ ......................  30 
Table 5: Visit windows  ................................ ................................ ................................ ..........................  32 
Table 6: Programming Recommendations at Baseline  ................................ ................................ ...................  36 
Table 7: Programming Recommendations at 4 Week Follow -Up ................................ ................................ ..... 38 
Table 8: Programming Recommendations at 8 Week Follow -Up ................................ ................................ ..... 39 
Table 9: Risks Related to Elevated Pacing  ................................ ................................ ................................ .. 44 
Table 10: Adverse Event and Device Deficiency Definitions  ................................ ................................ ..........  48 
Table 11: Adverse Event Classification Responsibilities  ................................ ................................ .................  50 
Table 12: Reporting Requirements  ................................ ................................ ................................ ...........  50 
Table 13: Subject Death Classification Responsibilities  ................................ ................................ ..................  52 
Table 14: Investigator Reports for the [LOCATION_002]  ................................ ................................ .....................  66 
Table 15: Spon sor Reports for the [LOCATION_002]  ................................ ................................ .........................  68 
Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events (n=2667)  .....................  72 
Table 17: Change History CIP V1.0 to CIP V2.0  ................................ ................................ .........................  81 
Table 18: Change History CIP V2.0 to CIP V3.0  ................................ ................................ .........................  86 
 
Table of Figures  
Figure 1: In Office Study Visits  ................................ ................................ ................................ ...............  22 
Figure 2: Sleep Function On During the Day  ................................ ................................ ..............................  25 
Figure 3: 95% Confidence Interval Widths for Various Proportions of 4 Week Safety and Tolerability Endpoint  ........  54 
 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 9 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 3.   Glossary  
Term/Abbreviation  Definition  
ACE Angiotensin Converting E nzyme  
ADE Adverse Device Effect  
ADL Activities of Daily Living  
AE Adverse Event  
ARB Angiotensin Receptor Blocker  
Bpm Beats per minute  
BNP B-type Natriuretic Peptide  
CIP Clinical Investigation Plan  
CH Concentric Hypertrophy  
CRF Case Report Form  
CTA Clinical Trial Agreement  
CV Curriculum Vitae  
Data protection authorization  A/an Authorization to Use and Disclose Personal 
Health Information/Research Authorization/other 
privacy language  
DD Device Deficiency  
Echo Echocardiography  
eCRF Electronic Case Report Form  
ERI Elective Replacement Indicator  
Ethics Committee  MEC/IRB/HREB/Ethics Board  
FAL Foreseeable Adverse Event List  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 10 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Term/Abbreviation  Definition  
GCP Good Clinical Practice  
Hall Walk  [ADDRESS_567263]  
MRI Magnetic Resonance Imaging  
NSR Non-Significant Risk  
NT-proBNP  N-terminal pro b -type Natriuretic Peptide  
NYHA  [LOCATION_001] Heart Association  
OC Oracle Clinical (electronic database)  
QOL Quality of Life  
RA Right Atrial  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 11 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Term/Abbreviation  Definition  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
SC Steering Committee  
SVT Supraventricular Tachycardia  
TIC Tachycardia induced dilated cardiomyopathy  
TIMPs  Tissue inibitors of metalloproteinases  
TriV Tri-ventricular  
UR Upper Rate  
UADE  Unanticipated Adverse Device Effect  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
WO Work Order  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 12 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 4.   Synopsis  
Title  REVAMP  Clinical Study  (REmodeling the Left Ventricle with Atrial 
Modulated Pacing)  
Clinical Study Type  Feasibility  
Product Name  [CONTACT_446179] a Sleep function  including:  
Kappa 700, Kappa 900, Adapta, Versa, Sensia, EnPulse,  Advisa, Advisa 
MRI, and additional Medtronic dual chamber pacemakers with the 
Sleep Function as they become market released  
Sponsor /Local Sponsor  Medtronic, Inc.  
Cardiac Rhythm and Heart Failure Clinical Research  
[ADDRESS_567264] NE  
Mounds View, MN [ZIP_CODE] U.S.A.  
[PHONE_2905] 
Indication under 
investigation   New therapy tested in heart failure w ith preserved ejection fraction 
(HFpEF ) patients with approved indications for pacing  
Investigation Purpose  The REVAMP  Clinical Study is a feasibility study in heart failure with 
preserved ejection fraction (HFpEF) patients who have normal to small 
left ventricular volumes and evidence of hypertrophy.   The pacemaker 
Sleep function will be used in order  to deliver a [ADDRESS_567265] Status  The study will be conducted using market -released Medtronic dual 
chamber pacemaker devices with a Sleep function and a Medtronic 
programmer.  The protocol will specify the programming of the Sleep 
Rate and Pacing Parameters in order to deliver elevated atrial pacing 
rates during the time w hen the patient is sleepi[INVESTIGATOR_007].  
Primary Objective (s) The primary objective of this study is to assess the feasibility of using 
elevated night pacing as a therapy for heart failure with preserved 
ejection fraction . 
Ancillary/Exploratory 
Objective(s)  Collect and characterize adverse events, quality of life, [ADDRESS_567266], echo measurements and blood biomarker data at Baseline and 
follow -up visits  
Study Design  The REVAMP Clinical Study will be a multi -center, prospective, 
randomized, single -blinded, clinical feasibility study.  
Randomization  Subjects will be randomized  at the 4 week follow -up visit to a 2:1 ratio  
to elevated night pacing ON or elevated night pacing OFF.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 13 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Sample Size  It is expected that up to 50 subjects may be enrolled to ensure 30 
subjects undergo elevated night pacing  at approximately 10 sites  in 
the [LOCATION_002]  only. 
Inclusion/Exclusion 
Criteria  Inclusion criteria:  
• Subject has  had a market released dual chamber Medtronic 
Pacemaker with a Sleep function for at least 3 months  
• Subject is stable on current medications   
• Subject has dyspnea with exertion  or diagnosed as NYHA Class II 
or III heart failure.  
• Subject has had a prior Echo in past 6 months with : EF ≥ 50%  
and Diastolic volume <80 ml/m2  
• Subject has e vidence of hypertrophy (indexed to body surface 
area: men 115 g/m2, women 95 g/m2  or indexed to height: men 
49.2 g/m2.7 , women 46.7 g/m2.7 ) or Relative Wall thickness 
>0.42, or Wall Thickness >1.2cm (posterior wall)  
• Subject is willi ng to sign and date the study Informed Consent 
Form 
• Subject is 18 years of age or older, or of legal age to give 
informed consent per local law  
• Subject is expected to remain available for follow -up visits  
Exclusion criteria:  
• Subject has permanent AF or AF noted on baseline interrogation 
rhythm strip  
• Subject has uncontrolled BP; (systolic pressure needs to be 
>100mmHg and <160mmHg on medications)  
• Subject has severe stenosis of the aortic or mitral valve, defined as 
a valve area ≤ 1.[ADDRESS_567267] has sever e regurgitation of the 
aortic or mitral valve.  
• Subject has symptomatic COPD requiring oxygen  
• Subject’s Pacemaker has less than 6 months of Pacemaker battery 
life 
• Subject had an aortic valve replacement (surgical or TAVR) 
procedure less than 9 months prior to enrollment  
• Subject’s programmed upper rate limit is less than 100 bpm 
because of concerns of elevated pacing  
• Subject is unable or unwilling to perform the [ADDRESS_567268] 
at all scheduled study visits  
• Subject is currently enrolled or planning to enro ll in a potentially 
confounding trial during the course of the study (co -enrollment in 
concurrent studies is only allowed when documented pre -approval 
is obtained from the Medtronic study manager)  
• Subject is pregnant  
• Subject meets any exclusion criteria r equired by [CONTACT_1769]  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 14 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Subject’s life expectancy is less than 12 weeks  
• Subject with a medical condition that precludes the patient from 
participation in the opi[INVESTIGATOR_871]  
• Subject has known coronary disease with Class II angina  
Study Procedures  and 
Assessments  In Office Visits: Study procedures, assessments and in-clinic data 
collection will be at Enrollment/ Baseline, 4 weeks, 8 weeks and 12 
week visits.  
Telephone Call Follow Up Visits : Subjects will be called at regular 
intervals after their Baseline visit: [ADDRESS_567269] can read using a finger pulse 
oximeter monitor that will be given to them at Baseline to use.  
Enrollme nt Baseline:  
• Informed Consent  
• Verification of Inclusion/Exclusion criteria  
• Subject Demographics  
• Medical History  
• Medications  
• Physical Assessment (including height, weight, heart rate 
and blood pressure)  
• NYHA classification  
• MN Living with Heart Failure Quest ionnaire  
• EQ-5D-5L Questionnaire  
• [ADDRESS_567270]  
• Blood  Draw 
• Echo  
• Device Interrogation (initial)  
• Save to media  (initial)  
• Program the sleep function to O N and program the pacing 
parameters  
• Subject observation of at least  [ADDRESS_567271] programming  
• Device Interrogation (final) - this needs to be completed 
at the end of the visit after programming has been 
completed  
• Save-to-Media  (final)  
24 Hour Telephone Call Follow Up Visit:  
• Symptom Assessment  
• Heart Rate  
5 Day  Telep hone Call  Follow Up Visit :  
• Sympto m Assessment  
• Heart Rate  
2 Week Telep hone Call  Follow Up Visit :  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 15 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Sympto m Assessment  
• Heart Rate  
 4 Week  In-Clinic Follow Up Visit (Randomization) : 
• Medications  
• Physical Assessment (including weight, heart rate and 
blood pressure)  
• NYHA classification  
• MN Living with Heart Failure Questionnaire  
• [ADDRESS_567272]  
• Blood Draw  
• Echo 
• Device Interrogation (initial)  
• Save-to-Media   (initial)  
• Program the sleep function to OFF if randomization 
assignment is OFF (and program  the pacing parameters)  
• Device Interrogation (final ) - this needs to be completed 
at the end of the visit after programming has been 
completed  
• Save-to-Media  (final)  
• Adverse Events (report new/assess ongoing AEs), Study 
Deviations, System Modifications, Dev ice Deficiencies, 
Crossovers (as they occur)  
6 Week Telephone Call Follow Up Visit:  
• Symptom Assessment  
• Heart Rate  
 8 Week  In-Clinic Follow Up Visit :  
• Medications  
• Physical Assessment (including weight, heart rate and 
blood pressure)  
• NYHA classification  
• MN Living with Heart Failure Questionnaire  
• EQ-5D-5L Questionnaire  
• [ADDRESS_567273]  
• Blood Draw  
• Echo 
• Device Interrogation (initial)  
• Save-to-Media  (initial)  
• Program the sleep function to OFF if subject still has  sleep 
function ON (and program the pacing param eters) 
• Device Interrogation (final) - this needs to be completed 
at the end of the visit after programming has been 
completed  
• Save-to-Media  (final)  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 16 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Adverse Events (report new/assess ongoing AEs), Study 
Deviations, System Modifications, Device Deficiencies,  
Crossovers (as they occur)  
10 Week  Telephone Call Follow Up Visit:  
• Symptom Assessment  
• Heart Rate  
 12 Week In-Clinic Follow Up Visit (Exit):  
• Medications  
• Physical Assessment (including weight, heart rate and 
blood pressure)  
• NYHA classification  
• MN Living with Heart Failure Questionnaire  
• [ADDRESS_567274]  
• Blood Draw  
• Echo 
• Device Interrogation (initial)  
• Save-to-Media   (initial)  
• Device Interrogation (final) - this needs to be completed 
at the end of the visit after programming has been 
completed  
• Save-to-Media  (final)  
• Adverse Events (report new/assess ongoing AEs), Study 
Deviations, System Modifications, Device Deficiencies, 
Crossovers  
Early study exit (prior to 12 week visit) :  
• Date of visit  
• Reason for exit  
• Adverse Events (report new/assess ongoing AEs), Stu dy 
Deviations, System Modifications, Device Deficiencies, 
Crossovers  
• Complete a Scheduled/Unscheduled Follow Up eCRF , if 
applicable  
Unscheduled Follow Up : 
The following are recommended at the discretion of the 
investigator if deemed necessary:  
• Physical Assessment (including weight, heart rate and 
blood pressure)  
• Medications  
• Echo 
• Blood draw  
• Device Interrogation  (initial)  
• Save-to-Media  (initial)  
• Program the Sleep Function to protocol  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 17 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Device Interrogation (final) - this needs to be completed at th e 
end of the visit after programming has been completed Save to 
Media  (final)  
 
The following are required:  
• Adverse Events (report new/assess ongoing AEs), Study 
Deviations, System Modifications, Device Deficiencies, Crossovers  
Safety Assessments  Levels of Troponin and NT-proBNP will be monitored at all in office 
visits to assess for ischemia and elevated wall stress that may indicate 
worsening heart failure.  All Adverse Events (AEs) that are potentially 
relevant will be  collected  which include  system-related, program ming-
related ,  cardiovascular and serious adverse event information 
throughout the study duration, starting at the time of signing the 
Informed C onsent  Form. All new and/or worsening AE inform ation, 
including all deaths will be collected throughout the clinical study 
duration. NT-pro BNP and Troponin will be collected at Baseline and at 
each subsequent in-office visit and changes will be assessed to ensure 
that the therapy is not leading to undue cardiac stress or ischemi a.  
Documented pre -existing conditions are not considered an AE unless 
the nature or severity of the condition has worsened.  
Endpoints  A number of measures of therapy safety, tolerability and efficacy will 
be explored as ancillary endpoints.    
 Statisti cs As a feasibility study, this study is not powered to meet any specific 
endpoints.   
5.   Introduction   
5.1.   Background  
An estimated 8.[ADDRESS_567275] heart failure (HF) by 2030 [1], and 
approximately 50 % of these HF patients will  have a preserved ejection fraction (HFpEF) [2].  In contrast 
to HF with reduced EF (HFrEF), no effective drug or device therapi[INVESTIGATOR_446122] n identified that improve 
the prognosis of the disease.  
A large proportion of HFpEF patients have hypertension and have a concentric hypertrophic  (CH) etiology 
described as an increased heart mass with increased relative wall thickness [3].  Cardiomyocytes in 
HFpEF are thicker than HFrEF, and collagen content is increased compared to controls [4].  Patients with 
concentric hypertrophy or evidence of increased wall thickness are characterized by [CONTACT_446143] [5] compared to normal controls.  HFpEF patients have 
relatively normal volumes and EF, but they have a reduced ability to adequately fill a stiffened left 
ventricle  (LV).   The impact of this diastolic dysfunction is more notable during exercise; HFpEF left 
ventricles are reliant on high left atrial pressures  to fill the LV  [4].   A search for a therapy that improves 
the compliance of the ventricle and improves early diastolic filling in these patients has not been 
successful.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567276] thickened ventricular 
walls and normal to small LV volumes.  One challenge is finding a therapeutic heart rate dose that does 
not cause undesirable symptoms in ambulatory HF patients and a dose that achieves a desirable level of 
dilation to improve filling.  Studies  in animal models show that the dilatory effects of rapid pacing 
diminishes once the elevated pacing rates are discontinued [6-8] ; the study of dose response to elevated 
atrial pacing rate also includes monitoring the reac tion of the heart to wit hdrawal of the pacing therapy.  
Clinical studies of SupraVentricular Tachycardia ( SVT) rates and durations that cause LV dilation are 
limited.  An extreme example of elevated heart rates promoting significant dilation and LV dysfunction 
comes from the clin ical observation of SVT induced cardiomyopathy.  Medi et al [9] reported 10% 
incidence of tachycardia induced dilated cardiomyopathy (TIC) in N=345 patients undergoing ablation for 
atrial tachycardia .   EF improved from 35 ± 11% to 59 ± 3% in the [ADDRESS_567277] -ablation.  At the time 
of ablation treatment, the patients with LV dilation were characterized by [CONTACT_446144] (117 ± 21 bpm vs 132 ± 33 bpm, p=0.05) and these patients repo rted that the duration of their 
symptoms started one or more years before seeking treatment.   Conventional wisdom is that patients 
with more rapid ventricular responses are symptomatic and seek treatment more quickly before dilation 
and cardiomyopathy can  occur from the rapid SVT.  
Animal studies that have been used to study TIC have reported LV dilation and increased pulmonary 
capi[INVESTIGATOR_446123] [ADDRESS_567278] rates such as 
240bpm [6].  However, the  extent of dilation and symptoms can be titrated by [CONTACT_446145]. A study in a porcine model of concentric hypertrophy showed that 100% atrial 
pacing at 170bpm increased LV end -diastolic volumes by 246% i n 4 weeks of pac ing compared to an 
increase of 25% at a more modest rate of 125 bpm at 2 weeks of pacing (about 30bpm higher than 
normal sinus rhythm).  The atrial pacing rate of  125bpm did not cause measurable changes in 
biomarkers including B -type natriuretic peptide [7].   
Since this therapy is delivered in an ambulatory patient, the choice of pacing rate and duration to achieve 
a therapeutic dilation of the LV must not induce intolerable symptoms.  A rate of 100bpm may be suitable 
for most HFpEF patients to respond favorably to stimulus rate, without symptoms.  The nominal pacing 
rate setting for “Activities of Daily Living”  (ADL)  in Medtronic pacemakers is 95bpm and the upper pacing 
rate (UR) is 130 bpm, so a sustained pacing rate of 100bpm is well within normal pacing range [10].  The 
acute hemodynamic response to elevated pacing rates in supi[INVESTIGATOR_446124] s been characterized 
to have a blunted inotropic response to pacing rates above 100bpm compared to normal subjects [5]. 
Stroke volumes have been shown to decrease from baseline as atrial pacing increases the rate above 
120bpm in supi[INVESTIGATOR_446125] [5, 11, 12] .  The force -frequency effect was reported to be positive at rates 20 
and 40bpm above intrinsic rates in patients with  left ventricular hypertrophy ( LVH) [11].  However, 
Inagaki et al [13] showed that the force frequency relationship can be biphasic in some patients with 
severe LVH, with a decrease in LV max +dp/dt  observed in some patients as pacing rates increased 
above a range of 100 -130bpm. At a structural level, HFpEF is typi[INVESTIGATOR_446126] v entricular (LV) mass -to-volume ratio or overt LV hypertrophy and 
fibrosis. A high prevalence of this structural phenotype in HFpEF was recently confirmed in the Treatment 
of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) t rial [22]. Despi[INVESTIGATOR_446127], about a quarter of patients had below -
normal chamber volumes.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 19 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Pacing at an elevated rate for 100% of the day may accelerate changes in cardiac structure, but could be 
symptomatic if elevated rates sustained for long periods of time.  Elevating heart rate for 5 hours during 
sleep at night may reduce the sensation to elevated rates and minimize symptoms for the patients.  
However, a heart rate dose of 5 hours will increase th e overall duration required to promote dilation in 
the LV chamber. A measurable change in LV volumes was measured at 2 weeks of 100% pacing at 
125bpm in animals [7], so a  reasonable therapy duration of 100bpm for 5 hours per day would  be 4 to 8 
weeks of pacing before changes in LV volume would be measured.   Measurement of biomarkers 
including matrix metalloproteinases (MMPs) and tissue inibitors of metalloproteinases (TI MPs) may be 
useful in understanding the time course of changes that lead changes in geometry.   The matrix 
metalloproteinases (MMPs) are part of an  enzymatic system that contribute to the remodeling of the 
extracellular matrix during rapid pacing -induced c ardiomyopathy  [14].  MMP -1, MMP -2, and MMP -3 were 
shown to increase in abundance at 7 days following initiation of rapid pacing, and were temporally 
related to a measured decrease in the collagen content as well as a lengthen ing of cardiomyocytes.   
TIMPs are also involved in inhibiting MMPs enzymatic activity and elevated TIMP -1 with reduction in 
MMPs were reported in HFpEF patients with LV hypertrophy [15].  
This proposed elevated atrial rate pacing therapy is aimed at improving exer cise capacity in HFpEF 
patients.  In order to safeguard patients, we propose measuring blood biomarkers including troponin and 
NT-proBNP in order to monitor indications that the therapy is not causing ischemia or worsening heart 
failure.   Natriuretic pept ide release occurs in response to myocardial stretch.  BNP and NT -proBNP are 
moderately elevated in HFpEF patients and may drop to normal levels in symptom -free periods [16].  The 
European Society of Cardiology guidelines p ropose a cut -off of >35 pg/ml for BNP and >125 pg/ml for 
NT-proBNP to identify chronic, stable HFpEF patients [17].  Thresholds for acute HF ha ve been reported 
as 100pg/ml for BNP and 300 pg/ml for NT -proBNP, which give sensitivity of 0.95 and 0.99 respectively, 
and negative predictive value of 0.94 and 0.98, respectively [18].    In a study of patients hospi[INVESTIGATOR_446128], a positive Troponin test  for myocardial infarction  was defined using a 
threshold of 1.0 µg/L or high er for cardiac Troponin I or 0.1  µg/L for cardiac Troponin T [19].  In an 
ambula tory chronic HFpEF population in 157 patients, the median value for Troponin I was 14 pg/mL 
(0.014 µg/L) [20].   A Troponin T threshold of 0.02 ng/mL (0.02 µg/L) was used in ambulatory HFpEF 
patients to detect myocardial injury; patients that had elevated T roponin T had an 78% rate of death or 
hospi[INVESTIGATOR_51530] 18 months compared to 13% [21].   
Metrics that will be used to evaluate whether there is a measurable therape utic effect of the elevated 
atrial pacing rate therapy include serial measurements of quality of life, [ADDRESS_567279] , device -
measured activity, echo measurements of volumes and diastolic function, and chronic c hanges in resting 
heart rate.  
5.2.   Purp ose 
Medtronic, Inc. is sponsoring the REVAMP  study, a multi -center, prospective, randomized, single -blinded, 
clinical feasibility study. The REVAMP  clinical study will include market -released pacemaker devices that 
incorporate  the Sleep function. The purpo se of the REVAMP  Clinical Study  is to assess whether elevating 
the atrial pacing rate for temporary periods of time is feasible.  Data will be collected to characterize 
whether temporary atrial pacing rate elevation can lead to beneficial left ventricular (LV) chamber 
dilation, improvements in exercise capacity, and quality of life in a specific etiology of Heart Failure with 
Preserved Ejection Fraction ( HFpEF ) patients who have normal to small LV chambers an d evidenc e of 
thickened walls.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 20 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 6.    Objective s and Endpoints  
6.1   Objectives  
 6.1.1.  Primary Objective s 
The primary objective of this study is to assess the feasibility of using elevated night pacing as a the rapy 
for HFpEF  patients . 
6.1.2.  Ancillary/Exploratory Objective s 
Adverse events, Minnesota Living With Heart Failure (MNLWHF) Questionnaire  responses , EQ-5D-5L 
Questionnaire responses, [ADDRESS_567280]  distance  and/or activity levels improve, it will be of interest to  see if the 
end diastolic volum e and mitral deceleration time correlate with improvements.   If the ther apy works as 
hypothesized, other echo measurements, including left ventricular ejection fraction (LVEF), might also 
change over time, although the direction and magnitiude of these effects are difficult to predict.  
Characterizing these effects will be an important goal of the feasibility study.  
6.2.   Endpoints  
As part of  the exploratory/ ancillary  safety, tolerability and efficacy effects described in  Section  14.1.   
Endpoint Definitions , it will be of interest to characterize changes in collected measurements from 
Baseline to 4 weeks, compare changes in collected measurements at 4 weeks to 8 weeks in the subjects 
randomized to the elevated night pacing ON arm to subjects randomized to the elevated night pacing 
OFF arm and compare changes in collected measurements at 12 weeks to Baseline, 4 and 8 weeks to see 
whether any therapeutic improvements are sustained after the therapy  is discontinued.  
6.2.1.   Primary Endpoint  
As a feasibility study, this study is not powered to meet any specific endpoints.   
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 21 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 7.   Study Design   
The REVAMP Clinical Study will be a multi -center, prospective, randomized, single -blinded, clinical  
feasibility  study. Subjects will be randomized in a 2:1 ratio to elevated night pacing ON or elevated night 
pacing OFF. 
It is expected that up to 50 subjects may be enrolled to ensure approximately 30 subjects undergo 
elevated night pacing  at approximatel y 10 sites in the [LOCATION_002]  to ensure enrollment completion 
within the pre -specified timeframe.  
The REVAMP study will be conducted as a Non -Significant Risk (NSR) IDE study. The REVAMP Research 
System does not include an investigational device; the ability to program a lower rate of 100 bpm is 
available in market -released pacemakers, and the Sleep function (which allows a different rate to be 
programmed for part of a 24 hour clock) is an approved feature in market -released pacemakers that will 
be use d in the clinical study. The study will be conducted in compliance with 21 CFR Parts 11, 50, 56, 
812.2(b)(1) . This study does not require an IDE submission to FDA.  
The Sleep Function will be programmed so that the pacemaker  can deliver an elevated pacing rate of [ADDRESS_567281] the following information: demographics, medical history, medications, standard 
physical, NYHA class, blood samples to measu re NT -proBNP, Troponin and other biomarkers, echo 
measurements, MN Living with Heart Failure Questionnaire , EQ-5D-5L Questionnaire, [ADDRESS_567282] -to-media, adverse events (including death), 
system modifications, and exit information.  The MN Living with Heart Failure Questionnaire was chosen 
to measure the  quality of life for subjects with heart failure , which includes a question on how well the 
subject is sleepi[INVESTIGATOR_21693].  
See Section  10.   Study Procedures . for further detail on study procedures and d ata collection as well as 
time-points for data collection.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 22 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
  
Figure 1: In Office Study Visits  
7.1.   Duration  
The study duration is expected to be approximately [ADDRESS_567283] is randomized. Subjects are 
anticipated to be in the study for approximately 12 weeks  completing in office visits at 
Enrollment/ Baseline, [ADDRESS_567284] ’s device programming will be returned to 
standard pacemaker  device settings per physician discretion at either [ADDRESS_567285] a lower 
Randomization 2:1  
at 4 weeks  (n=30)  
Enrollment  
Night Pacing ON 
(n~20)  
Night Pacing Off 
(n~10)  
At 8 weeks  
Night Pacing Off  
Exit @ 12 
weeks  
Baseline  
Begin Elevated Night Pacing 
On 
Exit if intolerable  
At 8 weeks  
Night Pacing Off  
 
Exit @ [ADDRESS_567286] the Baseline  visit and 5am the next morning 
when “Bed Time” will set the Sleep Rate at the pre -study lower rate of 60 -70bpm.  At the 4 week visit , 
there will be a safety assessment. Mea surements of NT -proBNP will be used to assess whether dilation of 
the heart is signalling worsening heart failure.  A Troponin assay will be used to ensure the elevated night 
pacing therapy isn’t leading to ischemia.   Subjects will be randomized at [ADDRESS_567287] shown that cessation of elevated pacing rates can reverse the dilation of the LV chamber; 
this study will monitor the time course of that reversal by [CONTACT_446146], 6  minute  walk tests  
and activity counts, and quality of life assessments.  
7.3.   Study Oversight  
The study will utilize a Steering Committee (SC). The SC is responsible for the scientific content of the 
study and provides input for the execution.  Members of the SC  may be study site investigators. The 
purpose of the SC is to provide unbiased opi[INVESTIGATOR_446129]. 
The SC will support the execution of the REVAMP  clinical study and provide guidance, feedback and 
direction to t he clinical study. The SC is comprised of the members as indicated below.  
Table 3: Steering Committee Members  
Committee Member  Contact [CONTACT_446147] S. Chung , MD 
 CEO and President  
The Christ Hospi[INVESTIGATOR_446130]  
[ADDRESS_567288]  
Cincinnati, OH [ZIP_CODE]  
([PHONE_9320]  
[EMAIL_8544]  
Markus Meyer, MD  
 Associate Professor of Medicine, Cardiovascular Medicine  
Department of Medicine  
Medicine -Cardiology, McClure Wing, [ADDRESS_567289]  
Burlington, VT [ZIP_CODE]  
(802) 847 -3734 
[EMAIL_8545]  
Michael Zile, MD  Professor of Medicine  
Medical University of South Carolina  
Department of Medicine  
Division of Cardiology  
[ADDRESS_567290], ART 7063  
MSC 592  
Charleston, SC [ZIP_CODE]  
(843) 876 -4761 
[EMAIL_8546]  
 
The Echocardiography  Core Laboratory  (Echo Core Lab) will review and analyze all echo data collected 
for the study . 
Further details for the Echo Core Lab are provided in CROs/Core Laboratories . 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 24 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 The Blood Core Laboratory  (Lab) will review and analyze all blood  data collected for the study . 
Further details for the Blood Core Lab are provided in  CROs/Core Laboratories . 
8.   Product Description  
8.1.   General  
All Medtronic implantable pacemakers and associated programmer and monitoring equipment must be 
market -released.  The Medtronic pacemakers must offer the Sleep Function feature.  The pacing 
parameter Lower R ate will be programmed to 100bpm, and the Sleep F unction will be used to lower the 
Sleep Rate  to the pre -study lower rate (50 -70 bpm) during 19 hours of the day.  The Sleep Function will 
be programmed to deliver the Sleep Rate between 5a.m.  and 11:30pm, using a Bed Time of 5a.m. and a 
Wake Time of 11:30p m.  Subjects will receive [ADDRESS_567291] a small to normal LV volume and evidence of LV hypertrophy 
and/or increased LV wall thickness will be selected for this study.  
8.3.   Study Components  
• All Medtronic dual chamber pacemaker s that have the Sleep Function  
• Medtronic market -released programmers  
• Compatible market -released leads  
• Finger Pulse Oximeter Monitor  (will be provided to the site)  
• Echocardiography  machine capable of recording and exporting echo data in digital format  
• Access to dry ice to ship blood samples  
• Computer with high speed internet access using a web browser compatible with the electronic 
data management system for electronic database entry  
8.4.   Product Use  
The Sleep function  in all Medtronic market -released devices was designed to temporarily substitute the 
programmed Lower Rate with a slower pacing rate  (Sleep Rate)  during the time of day that the patient 
normally sleeps.  This feature c an be programmed to lower the rate to the Sleep Rate at “Bed time” and 
to increase the rate back to th e Lower Rate at “Wake time”.  The design intent of this feature was that 
the slower Sleep Rate can be programmed to occur during any window in the 24  hour clock; the 
difference between Bed Time and Wake Time must be a minimum of 2 hours .  The REVAMP study 
proposes to use the lower Sleep Rate for 18 hours during the day, in order to elevate the Lower Rate to 
100bpm and pace the atrium at an elevated rate at night.  For the REVAMP study, we specify the Lower 
Rate programmed at 100bpm, with the Sleep Rate programmed to the pre -study value of the Lower Rate 
(e.g. 60bpm).  
 
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 25 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
  
Figure 2: Sleep F unction  On During the Day  
 
The Sleep Function will be programmed to deliver the Sleep Rate between 5a.m. and 11:30pm, using a 
Bed Time of 5a.m. and a Wake Time of 11:30pm.    
The Sleep Function was designed to operate in conjunction with Rate Responsive pacing; however, the 
Rate Pro file Optimization feature that automatically optimizes was not developed with 5 hours of 100bpm 
imposed on patients.  Therefore, Rate Profile Optimization will be turned OFF while the Sleep Function is 
programmed ON.    
The Sleep Function is suspended follo wing any parameter programming operations.  If the Sleep Function 
is suspended, the pacing rate will immediately return to the programmed Lower Rate (100bpm per this 
protocol) until the next Bed Time is reached.  At the initial programming visit of this pr otocol, subjects 
will be evaluated for whether they are symptomatic at a Lower Rate of 100bpm.  Subjects will leave the 
Baseline  visit experiencing a Lower pacing rate of 100 bpm until 5am the next morning, when Bed Time 
for the Sleep Function is reached.  After the elevated pacing has been turned ON, a ny telemetry 
activation, such as programming, magnet application or CareLink transmission  will suspend the Sleep 
Function and the pacemaker will immediately return to the Lower Rate of 100  bpm until 5am.  
If a pacemaker reaches  Estimated Replacement Indicator ( ERI), the device will automatically turn OFF 
the Sleep Function and reprogram the pacemaker to VVI [ADDRESS_567292] meet all of the inclusion criteria and 
none of the exclusion criteria. Notification of site activation from Medtronic, and appro val from the IRB of 
the REVAMP Clinical Investigation Plan (CIP), Informed Consent Form (IC Form), Authorization to Use 
and Disclose Personal Health Information/Research Authorization/other privacy language (data protection 
authorization) as required by [INVESTIGATOR_23057] w, and any other applicable documents must be obtained prior to 
enrolling subjects in the study.     
9.3.   Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be eligible to participate in the study:  
INC 1: Subject has had a market released dual chamber Medtronic Pacemaker  with a Sleep 
function  for at least 3 months  
INC 2: Subject is stable on current medications  
INC 3: Subject has dyspnea with exertion  or diagnosed as NYHA Class II or III heart failure.  
INC 4: Subject has had a  prior Echo in past 6 months  with: EF ≥ 50% and Diastolic volume <80 
ml/m2  
INC 5: Subject has e vidence of hypertrophy (indexed to body surface area: men 115 g/m2, 
women 95 g/m2  or indexed to height: men 49.2 g/m2.7 , women 46.7 g/m2.7 ) or Relative Wall 
thickness >0.42, or Wall Thickness >1.2cm (posterior wall)  
INC 6: Subject is willing to sign and date the study Informed Consent Form (IC Form) and 
Authorization to Use and Disclose Personal Health Information/Research Authorization/other 
privacy language ( data protection authorization) as required by [CONTACT_446148] 7: Subject is 18 years of age or older, or of legal age to give informed consent per local law  
INC 8: Subject is expected to remain available for follow -up visits  
9.4.   Exclusion Criteria  
Subjec ts must not meet any of the following exclusion criteria to be eligible to participate in the study:  
EXC 1: Subject  has permanent AF or  AF noted on baseline interrogation rhythm strip  
EXC 2: Subject has uncontrolled BP; (systolic pressur e needs to be >100mmHg and <160mmHg 
on medications)  
EXC 3: Subject has severe stenosis of the aortic or mitral valve, defined as a valve area less than 
or equal to 1.[ADDRESS_567293] has severe regurgitation of the aortic or mitral valve.  
EXC 4: Subject has symptomatic COPD  requiring oxygen  
EXC 5: Subject’s Pacemaker has less than 6 months of Pacemaker battery life  
EXC 6: Subject had an aortic valve replacement (surgical or TAVR) procedure less than 9 months 
prior to enrollment.  
EXC 7: Subject’s programmed upper rate lim it is less than 100 bpm because of concerns of 
elevated pacing  
EXC 8: Subject is unable or unwilling to perform the [ADDRESS_567294] at all scheduled study 
visits 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 27 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 EXC 9: Subject is currently enrolled or planning to enroll in a potentially confounding tri al during 
the course of the study (co -enrollment in concurrent studies is only allowed when documented 
pre-approval is obtained from the Medtronic study manager)  
EXC 10: Subject is pregnant  
EXC 11: Subject meets any exclusion criteria required by [CONTACT_446149] w 
EXC 12: Subject’s life expectancy is less than 12 weeks  
EXC 13: Subject with medical condition that precludes the patient from participation in the 
opi[INVESTIGATOR_446131] 14: Subject has known coronary disease with Class II angina  
9.5.   Minimiz ation of Bias  
Selection of subjects , treatment of subjects, and evaluation of study data are potential sources of bias. 
Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Subjects will be evaluated at Baseline to confirm eligibility for enrollment with defined 
inclusion/exclusion criteria prior to randomization  
• Subjects will be randomly assigned to their treatment assignment  
• Subject demographics and medical history will be collected at Baseline and differences that may 
affect endpoints will be identified  
• Subjects will be blinded to their randomization assignment  
• Data collection requirements and study procedures will be standardized across all sites  
• All study  site personnel and Medtronic personnel will be trained on their respective aspects of the 
study using standardized training materials, and required to follow the CIP  
• Monitoring visits will be conducted according to the study -specific monitoring plan . 
• A single Echocardiography Core Lab will be u sed to analyze the echo data, and members of the 
core lab will be blinded to subject’s randomization  
• A single Blood  Core Lab will be used to analyze the blood  data 
• Registration of the trial on C linical Trials.gov  
In summary, potential sources of bias that may be encountered in this clinical study have been 
considered and minimized by [CONTACT_54415].  
10.   Study Procedures   
Prior to performing study related p rocedures, all sites must have IRB approval  and documentation from 
Medtronic of site readiness . 
Medtronic representatives may perform the following activities at the study sites during the study, if 
appropriately trained and under supervision of the Principal Investigator:  
• Study training relevant and pertinent to the involvement of personnel conduct ing study activities 
and investigator responsibilities  
• Technical support at all visits (e.g. programming of the pacemakers according to study 
requirements, performing device interrogations/save -to-media, etc.), but no CRF data entry shall 
be performed by M edtronic personnel  
• Monitoring activities  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567295]’s heart failure must be qualified practitioners and 
experienced in the diagno sis and treatment of subjects with heart failure.  
The role of the principal investigator [INVESTIGATOR_54365] -to-day conduct of the clinical 
investigation as well as ensure data integrity and the rights, safety and well -being of the subjects  
involved in the clinical investigation.  
The principal investigator [INVESTIGATOR_67417]:  
• Be qualified by [CONTACT_8640], training, and experience to assume responsibility for the proper 
conduct of the clinical investigation  
• Be experienced in the field of application  
• Disclose potential conflicts of interest  that interfere with the conduct of the clinical investigation 
or interpretation of results  
The principal investigator [INVESTIGATOR_389391]:  
• Has the required number of e ligible subjects needed within the recruitment period  
• Has a qualified investigational site team and adequate facilities available for the foreseen 
duration of the clinical investigation   
Site personnel training and delegation will be completed prior to par ticipation in this clinical study.  
10.2.   Role of the Sponsor Representative  
Sponsor representatives may provide support as required for the study under supervision of the PI, 
including:  
• Provide study training relevant and pertinent to the involvement of personnel conducting study 
activities and Investigator responsibilities  
• Technical support at  all visits under the supervision of a study Investigator, but no data entry, 
shall be performed by [CONTACT_389403]  
• Monitoring activities  
10.3.   Site Activation  
During the activation process (prior to subject enrollment), Medtronic will train site personnel on the CIP, 
relevant standards and regulations, obtaining informed consent, and on data collection and reporting  
tools. If new members join the study site team, they will receive training on the applicable clinical study 
requirements relevant to their role before contributing to the clinical study. For new members, local IRB  
notification requirements must be met, a s well as Medtronic requirements.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 29 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 A Clinical Trial Agreement (CTA) or Work Order (WO) shall be entered into effect by [CONTACT_13735], the 
participating investigation site and/or the principal clinical investigator at each investigational site as per 
local legal  requirements, and returned, fully executed, to Medtronic prior to the commencement of any 
study activities. Financial aspects of conducting and reporting a study will be specified in the agreement. 
By [CONTACT_446150] e indicates approval of the CIP.  
Prior to performing study related activities, all sites must have IRB approval.  
All local and regional regulatory requirements will be fulfilled prior to site activation and enrollment of 
subjects into the study. Each study  site must have written documentation from Medtronic of site and 
investigator readiness before beginning any study -related activities. Requirements for activation may 
include, but are not limited to the following:  
• Written documentation of IRB approval of  the current version of the CIP, IC Form, Authorization 
to Use and Disclose Personal Health Information/Research Authorization/other privacy language 
(data protection authorization) as required by [CONTACT_2371], subject materials, and voting list (as required 
by [CONTACT_446151])   
• Fully executed CTA or WO on file with the sponsor  
• Investigator Agreement  
• Current Curriculum Vitae (CV )  
• Financial Disclosure Agreement  
• Documentation of delegated tasks  
• Documentation of study site personnel training  
Additional requirements impo sed by [CONTACT_137314], if applicable .  
Medtronic will provide each study site  with documentation of study site/investigator readiness; this letter 
must be received prior to subject enrollment . 
10.4.   Equipment Requirements  
The following equipment must be available at each site to support study activities:  
• Medtronic market -released programmers  
• Echocardiography machine capable of recording and exporting echo data in digital format  
• Access to dry ice for shipment of blood samples  
• Computer wit h high speed internet access using a web browser compatible with the electronic 
data management syste m for electronic database entry  
The maintenance and calibration of the programmers used for this study will be assessed outside of this 
clinical study. Sit es are responsible for maintaining and calibrating non -programmer equipment used in 
the course of this study in accordance with established site practice. Records should be kept and able to 
be provided upon request by [CONTACT_446152].  
10.5.    Schedule of Events  
Clinical data is collected at designated time points throughout the study as indicated in Table [ADDRESS_567296] be done, for which instructions are provided in an 
Echocardiography Handbook (provided under sep arate cover) . A blood draw must also be done, 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 30 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 (instructions are provided under separate cover.)  The device programming should occur after all other 
study procedures are complete, except for the final device interrogation and save -to-media.  The EQ-5D-
5L Que stionnaire will only be collected at the Baseline and 8 week visits.  
In addition to eCRF data, non -eCRF data will be collected to include  device interrogation files/save -to-
media and digital echo data.  
Table 4: Study Procedures  
Study Procedure  Enroll -
ment Baseline  Telephone 
Call Follow Up 
Visits 
(24 Hour, 5 
days, 
2 weeks,  
6 weeks,  
10 weeks)  4 week 
visit 8 week 
visit 12 week 
visit 
(Study 
Exit) Early 
Study  
Exit  
 Unscheduled 
Visit 
Informed consent  x       
  
Inclusion/exclusion 
assessment  x x      
  
Demographics   x      
  
Medical History   x      
  
Medications   x X x X x X x** 
Physical 
Assessment   x  x X x  x** 
NYHA class   x  x X x   
MN Living with 
Heart Failure 
Questionnaire   x  x X x   
EQ-5D-5L 
Questionnaire   x   X    
[ADDRESS_567297]   x  x X x   
Echo  x  x X x  x** 
Blood Draw   x  x X x  x** 
Initial Device 
Interrogation/Save -
to-media   x  x X x x x** 
Device 
Programming  
 
  x  x* x*  x** x** 
Final Device 
Interrogation / 
Save-to-Media   x  x X x x x** 
At least [ADDRESS_567298] device 
programming   x       
Symptom 
Assessment    X x X x  x** 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 31 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Study Procedure  Enroll -
ment Baseline  Telephone 
Call Follow Up 
Visits 
(24 Hour, 5 
days, 
2 weeks,  
6 weeks,  
10 weeks)  4 week 
visit 8 week 
visit 12 week 
visit 
(Study 
Exit) Early 
Study  
Exit  
 Unscheduled 
Visit 
Heart Rate  (using 
finger oximeter)    X     
  
Crossover     
                              As they occur  
 
 System 
modifications   
As they occur  
Adverse events 
(AEs)/Death   
As they occur  
Device Deficiencies   
As they occur  
Study deviations   
As they occur  
Study Exits  As they occur  
 
* See programming recommendations for the follow up visit  
** If deemed  necessary by [CONTACT_446153] [ADDRESS_567299] be accompanied by a deviation.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 32 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 5: Visit windows  
Visit  Must occur between  After reference visit  
Baseline  0 - 30 days  Enrollment  
24 Hour Phone Call  0-1 day  Baseline  
5 Day Phone Call  2 - 8 days  Baseline  
2 Week Phone  Call 11 – 17 days Baseline  
Randomization – 4 week 
visit 21 – 35 days  Baseline  
6 Week Phone Call  39 – 45 days  Baseline  
8 Week Visit  49 – 63 days Baseline  
10 Week Phone Call  67 – 73 days  Baseline  
12 Week Visit (Exit)  77 - 91 days Baseline  
 
10.6.    Prior and Concomitant Medications  
There are no medication restrictions in the study unless they are investigational and may confound the 
study results, in which case, prior approval would be needed from Medtronic.  
At baseline, 4, 8, and 12 week  follow up visits, all telephone call follow u p visits,  unscheduled visits, and 
early exit visits, cardiovascular  medications and the use of insulin will be collected.  Cardiovascular 
medications inclu de: ACE inhibitors, ARBs, MRAs, antiarrhythmics, anti -coagulants an d antiplatelets, 
antihypertensives , antilipi[INVESTIGATOR_7509] ( incl. statins), ß-blockers , calcium channel blockers, diuretics, digitalis, 
inotropes, nitra tes, digoxin, and vasodilators.  
10.7.    Subject Consent  
Informed consent is defined as a legally effective documented confirmation of a subject’s voluntary 
agreement to participate in a particular clinical study after information has been given to the subject on 
all aspects of the clinical study that are releva nt to the subject’s decision to participate. This process 
includes obtaining an Informed Consent  Form and an Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language (data protection authorization) as required by 
[CONTACT_181010]’s IRB, and Medtronic,  and signed and dated by [CONTACT_3433] e subject 
and the Principal Investigator [INVESTIGATOR_169225]. A subject may only consent after information 
has been given to the subject on all aspects of the clinical study that are relevant to the subject’s decision 
to participate.  
Prior to enroll ing subjects, each site must have documented IRB approval of the Informed Consent  Form 
(IC Form) and an Authorization to Use and Disclose Personal Health Information/Research 
Authorization/other privacy language (data protection authorization) as required by [CONTACT_2371] . Any changes to a 
previously approved Informed Consent Form throughout the course of the study must be reviewed and 
approved by [CONTACT_446154] -
consent a study subject. The do cument(s) must be controlled (i.e. versioned and dated) to ensure it is 
clear which version(s) were approved by [CONTACT_169267]. All important new information should be 
provided in written form to new and existing subjects throughout the study. If re levant, all affected 
subjects must be asked to confirm their continuing informed consent in writing.   
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567300] 
be conducted by [CONTACT_458] [INVESTIGATOR_169225], and the Informed Conse nt Form 
and an Authorization to Use and Disclose Personal Health Information/Research Authorization/other 
privacy language (data protection authorization) , as required by [CONTACT_2371] , must be given to the subject in a 
language he/she is able to read and understand . 
The process of obtaining informed consent shall:  
• Ensure that the principal investigator [INVESTIGATOR_446132].  
• Include all aspects of the clinical study that are relevant to the subject's decision to participate 
throughout the clinical study.  
• Avoid any coercion or undue improper influence on, or inducement of the subject to participate.  
• Not waive or appear to waive the subject’s legal rights.  
• Ensure the Informed Consent  Form and an Authorization to Use and Disclos e Personal Health 
Information/Research Authorization/other privacy language , (data protection authorization) as 
required by [CONTACT_2371] , are given to the subject in a non -technical language the subject is able to read 
and understand.  
• Provide ample time and opportu nity for the subject to read and understand the Informed 
Consent Form to inquire about details of the study, and to consider participation. All questions 
about the study should be answered to the satisfaction of the subject.  
• Include a personally dated sign ature of the subject acknowledging that their participation in the 
study is voluntary.  
• Include a personally dated signature [CONTACT_3265] [CONTACT_458] [INVESTIGATOR_446133] , as required by [CONTACT_1769].  
• Provide the subject with a copy of the Informed Consent  Form and an Authorization to Use and 
Disclose Personal Health Information/Research Authorization/other privacy language (data 
protection authorization) as required by [CONTACT_2371] . 
• Ensure subjects are notified of a ny significant new findings about the study that become 
available during the course of the study which are pertinent to the safety and well -being of the 
subject, as this could impact a subject’s willingness to participate in the study.  
If the informed consent is obtained the same day the subject begins participating in study -related 
procedures, it must be documented that consent was obtained prior to participation in any study -related 
procedures. It is best practice for the process of obtaining the informed  consent to be documented in the 
subject’s case history, regardless of circumstance.  
In the event the subject cannot read and/or write, witnessed (impartial third party) informed consent will 
be allowed, provided detailed documentation of the process of obtaining the informed consent is 
recorded in the subject’s case history and the witness signs and dates the Informed Consent  Form. 
Informed consent shall be obtained through a supervised oral process. An independent witness must be 
present throughout the pr ocess. The IC Form  and any other information must be read aloud and 
explained to the prospective subject, if allowed by [CONTACT_1769]. The witness signs and personally dates the 
Informed Consent Form attesting that the information was accurately explained and that informed 
consent was freely given. The subject should “make his mark” (sign or otherwise physically mark the 
document so as to indicate consent) on the Informed Consent Form as well. The Informed Consent Form 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567301] be filed in the hospi[INVESTIGATOR_307]/clinical chart and/or with  
the subject’s study documents.  
The Informed Consent  Form and an Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language (data protection authorization) as required by 
[CONTACT_2371], must be available for monitoring, auditing and regulatory inspections. Any Medtronic personnel who 
support the initial programming of the elevated night pacing  must be able to review the subject’s signed 
and dated Informe d Consent  Form and verify its completeness prior to proceeding with the programming . 
In the event the designated Medtronic personnel identify the IC Form as being incomplete, the 
programming  will not be allowed to occur until the consent of the subject can  be adequately and 
appropriately obtained.  
10.8.    Enrollment  
A subject is considered enrolled when the Informed Consent Form has been signed and dated . The date 
the subject signed the Informed Consent  Form and an Authorization to Use and Disclose Personal  Health 
Information/Research Authorization/other privacy language (data protection authorization) as required by 
[CONTACT_2371], must be documented in the subject’s medical records. Enrollment can be a stand -alone visit or can 
occur on the same day as the Baseline Visit. Once consent is obtained, report adverse events/deaths, 
study deviations an d subject exits as they occur.  
10.9.    Baseline Visit  
The B aseline Visit must occur within [ADDRESS_567302]’s 
medical chart. If eligibility verification at the Baseline visit shows that the subject does not meet all 
inclusion and exclusion criteria the subject must be exited. The device programming should occur after all 
other study procedures are complete, except for the final device interrogation and save -to-media.   
The subject will be provided  at the Baseline V isit with a finger pulse oximeter monitor to use at home 
during the telephone follow -up visits to measure their heart rate.  The finger pulse oximeter should be 
returned to the site at the study exit visit.  
In the event a subject experiences symptoms  at home after the Baseline visit, the subject will be 
instruc ted to seek m edical help to deter mine the cause of the symptoms.  
The following information is required to be collected at the Baseline visit:  
• Verification of Inclusion/Exclusion criteria  
• Subject Demographics  
• Medical History  
• Medications  
• Physical Assessment (including height, weight, heart rate and blood pressure)  
• NYHA Class  
• MN Living w ith Heart Failure Questionnaire  
• EQ-5D-5L Questionnaire  
• [ADDRESS_567303]  
• Echo*  
• Blood Draw ** 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 35 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Device Interrogation  (initial)  
• Save-to-Media  (initial)  
• Device Programming, see Table 6. 
• Subject observation of at least  [ADDRESS_567304] programming  
• Device Interrogation  (final) - this needs to be completed at the end of the visit after 
programming has been completed  
• Save-to-Media  (final) 
*The Baseline echo must be sent to the Echocardiography Core Laboratory (echo core lab) for analysis, 
with a copy of the echo remaining  at the site. Details of the echo core lab, type of echo to be performed, 
and the review process will be provided in an Echocar diography Handbook (p rovided under separate 
cover).  
** The baseline blood sample must be sent to the Blood Core Laboratory for an alysis. Details of the 
blood  core lab  and the blood draw process will be provided under separate cove r. 
10.9.1.   Programming Recommendations at Baseline   
Table 6 lists the programming recommendations  applicable to all study subjects. At the Baseline visit, 
when the Sleep Function is turned ON, the pacing rate  will remain at the 100 bpm setting until 5:00 am 
the next day.  Use of AAI (R) programming is not recommended due to the possibility of AV block 
occurring at higher rate pacing.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 36 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 6: Programming Recommendations at Baseline  
Parameter  Elevated Night Pacing ON   
Sleep function  On† 
Sleep Rate  Whatever was previously 
programmed as Lower Rate  
Bed Time  05:00 (5am) †† 
Wake Time  23:30 (11:30pm) †† 
Pacing Parameter: Lower Rate  100 bpm  
Rate response  ON (if previously programmed 
ON) 
ADL > 105 bpm  
Rate Profile Optimization  Off 
ADL Setpoint  Previously programmed value as 
ADL Setpoint plus 5  
UR Setpoint  Previously programmed value as 
UR Setpoint plus 5  
† After the Sleep Function is turned O N, any telemetry  activation, such as programming, magnet application or CareLink 
transmission – the ongoing sleep function will be terminated which means the pro grammed rate will jump to 100 b pm. 
If ERI is detected, the pacemaker will turn the Sleep function to Off  and th e Lower Rate will be reprogrammed to VVI 65  
automatically . 
††If the subject’s normal sleep hours are not during 11:30 pm – 5:[ADDRESS_567305] will likely be sleepi[INVESTIGATOR_007].  
10.10.    Scheduled Follow -Up Phone Calls  
The participating investigator/study coordinator will attempt to reach the subject for phone calls at  
regular intervals after the Baseline visit ( 24 hours, 5 days, 2 weeks, 6 weeks, 10 weeks ) to inquire ab out 
symptoms  and medications . A standard set of questions to use when inquiring about symptoms and 
medications will be provided to the sites.  Subjects will also be asked  their heart rate , which the subject 
can read using a finger pulse oximeter monitor  that will be given to them at Baseline to use . 
10.11.    Randomization  (4 Week Follow -Up) 
Subjects will be assigned to a group at random during the randomization visit. Rando mization will occur 
at 4 weeks.  
Subjects will be randomized in a 2:1 ratio to the Elevated Night Pacing ON or to the Elevated Night 
Pacing OFF grou p. 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 37 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Sites will receive this randomization assignment from the randomization schedule, which is automatically 
populated on the eCRF . 
Procedures to be performed and data to be collected at Rando mization include:  
• Physic al Assessment (including  weight, heart rate , symptoms,  and blood pressure)   
• Medications  
• NYHA Class  
• MN Living with Heart Failure Questionnaire  
• [ADDRESS_567306]  
• Echo* 
• Blood Draw ** 
• Randomization assignment  
• Device Interrogation / (initial)  
• Save-to-Media (initial)  
• Device Programming, see Table 7: Programming Recommendations  at 4 Week Follow -Up 
• Device Interrogation (final) - this needs to be completed at the end of the visit after 
programming has been completed  
• Save-to-Media  (final)  
• Adverse Events (report new/assess ongoing AEs), Study Deviations, System Modifications, Device 
Deficiencies, Crossovers (as they occur)  
*The echo must  be sent to the Echo Core Laboratory for analysis, with a copy of the echo remaining at 
the site. Details of the Echo Core Laboratory, type of echo to be performed, and the review process will 
be provided in an Echocardiography Handbook (provided under sep arate cover ). 
** The blood sample must be sent to the Blood Core Laboratory for analysis . Details of the blood core lab  
and the blood draw process will be provided under separate cover.  
For any subject who has an abnormal NT -proBNP, troponin or LVEF measurement as defined in the 
Safety Assessment ( Section 10.19.    Assessment of Safety ) and the investigator elects to discontinue 
elevated night paci ng, a subsequent visit will be necessary for the elevated night pacing to be 
programmed OFF if the subject was randomized to the elevated pacing ON arm.  The subject should 
continue to be followed through the 12 week  visit. 
10.11.1 .   Blinding  
The study will be single blinded (i.e., subject s are blinded to their group) to reduce bias for the duration 
of the study. It is essential that sites, including echocardiography staff, take special precaution to 
maintain the blind for the entire portion of  the subject’s participation in the study. Other options to 
maintain the blind may be applied per investigational site research procedure.  Refer to the Randomization 
and Blinding Plan for specific details.  
10.11.2.   Programming Recommendations at 4 Week Follow -Up 
Table 7 lists the programming recommendations  applicable to study subjects, according to their 
respe ctive randomization assignment.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 38 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 7: Programming Recommendations  at 4 Week Follow -Up 
Parameter  Elevated Night Pacing ON   Elevated Night Pacing OFF   
Sleep function  ON†  
Per physician discretion  
Sleep Rate  Whatever was prev iously 
programmed as Lower Rate  Per physician discretion  
Bed Time  05:00 (5am) †† Per physician discretion  
Wake Time  23:30 (11:30pm) †† Per physician discretion  
Pacing Parameter: Lower Rate  100 bpm  Per physician discretion  
Rate response  ON (if previously programmed 
ON) Per physician discretion  
ADL > 105 bpm  Per physician discretion  
 
Rate Profile Optimization  OFF Per physician discretion  
 
ADL Setpoint  Previously programmed value as 
ADL Setpoint plus 5  Per physician discretion  
UR Setpoint  Previously programmed value as 
UR Setpoint plus 5  Per physician discretion  
† After the Sleep Function is turned O N, any telemetry activation, such as programming, magnet application or CareLink 
transmission – the ongoing sleep function will be terminated which means the programmed rate will jump t o 100 bpm. 
If ERI is detected, the pacemaker wil  automatically  turn the Sleep function to Off  and program the pacing mode and rate to VVI  65. 
††If the subject’s normal sleep hours are not during 11:30 pm – 5:[ADDRESS_567307] be performed / data are required to be collected at the 8 week visit:  
• Physical Assessment (including weight, hea rt rate , symptoms  and blood pressure)  
• Medications  
• NYHA Class  
• MN Living w ith Heart Failure Questionnaire  
• EQ-5D-5L Questionnaire  
• [ADDRESS_567308]  
• Echo* 
• Blood Draw ** 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 39 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Device Interrogation (initial)  
• Save to media  (initial)  
• Device Programming , see Table 8. 
• Device Interrogation (final) - this needs to be completed at the end of the visit after 
programming has been completed  
• Save-to-Media (final)  
• Adverse Events (report new/assess ongoing AEs), Study Deviations, System Modifications, Device 
Deficiencies, Crossovers (as they occur)  
*The echo must be sent to the Echo Core Laboratory for analysis, with a copy of the echo remaining at 
the site. Details of the Echo Core Laboratory, type of echo to be performed, and the review process will 
be provided in an Echocardiography  Handbook (provided under separate cover).  
** The blood sample must be sent to the Blood Core Laboratory for analysis . Details of the b lood core lab  
and the blood draw process will be provided under separate cove r. 
 10.12.1.    Programming Recommendations  
Table [ADDRESS_567309] elevated 
night pacing ON. (All subjects should have elevated night pacing OFF by [CONTACT_2671] 8 week visit.)  
Table 8: Programming Recommendations at 8 Week Follow -Up 
Para meter  Elevated Night Pacing OFF   
Sleep function   
Per physician discretion  
Sleep Rate  Per physician discretion  
Bed Time  Per physician discretion  
Wake Time  Per physician discretion  
Pacing Parameter: Lower Rate  Per physician discretion  
Rate response  Per physician discretion  
ADL Per physician discretion  
Rate Profile Optimization  Per physician discretion  
 
ADL Setpoint  Per physician discretion  
UR Setpoint  Per physician discretion  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567310] to the study site. Routine visits or 
other planned visits are not collected.   
The following information is recommended  to be collected at an unscheduled follow -up visit  at the 
discretion of the investigator if deemed necessary : 
• Physical Assessment (including weight, heart rate , symptoms  and blood pressure)  
• Medication changes  
• Echo* 
• Blood draw ** 
• Device Interrogation (initial)  
• Save-to-Media  (initial)  
• Program the Sleep Function and parameters to protocol  
• Device Interrogation (final) - this needs to be completed at the end of the visit after 
programming has been completed  
• Save to Media  (final)  
 
The following is required:  
 
• Adverse Events (report new/assess ongoing AEs)  
• Study Deviations  
• System Modifications  
• Device Deficiencies  
• Crossovers  
*The echo must be sent to the Echo Core Laboratory for analysis, with a copy of the echo remaining at 
the site. Details of the Echo Core Laboratory, type of echo t o be performed, and the review process will 
be provided in an Echocardiography Handbook (provided under separate cover ). 
** The blood sample must be sent to the Blood Core Laboratory for analysis . Details of the blood core lab  
and the blood draw process wi ll be provided under separate cover.  
10.14.   12 Week Visit ( Study Exit ) 
At the completion of the [ADDRESS_567311] be performed / data  
are required to be collected at the 12 week  visit: 
• Medications  
• Physical Asses sment (including weight, heart rate, symptoms and blood pressure)  
• NYHA Class  
• MN Living with Heart Failure Questionnaire  
• [ADDRESS_567312]  
• Echo*  
• Blood Draw**  
• Device Interrogation (initial)  
• Save to Media (initial)  
• Program the sleep function and pacing para meters to elevated night pacing OFF (see Table 8) for 
subjects who still have their pacemaker programmed to elevated night pacing ON.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 41 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • Device Interrog ation (final) - this needs to be completed at the end of the visit after 
programming has been completed  
• Save-to-Media (final)  
• Adverse Events (report new/assess ongoing AEs), Study Deviations, System Modifications, Device 
Deficiencies  
* The echo must be sen t to the Echo Core Laboratory for analysis, with a copy of the echo remaining at 
the site. Details of the Echo Core Laboratory, type of echo to be performed, and the review process will 
be provided in an Echocardiography Handbook (provided under separate c over). 
** The blood sample must be sent to the Blood Core Laboratory for analysis . Details of the blood core lab  
and the blood draw process will be provided under separate cover . 
10.15.    Study Exit 
Subjects will be exited from the study for any of the following situations:  
• Study completed  
• Subject death  
• Subject lost to follow -up 
• Subject chooses to exit (i.e. revokes informed consent)  
• Investigator withdraws subject  
• Subject has intolerable symptoms that cannot be alleviated by [CONTACT_14173]  
A Study Exit eCRF need s to be completed for all subjects with the date and reason for the exit. The 
following should also be collected if applicable : 
• Scheduled/Unscheduled Follow Up eCRF, if applicable  
• Adverse Events, Study Deviations, System Modifications, Device Defic iencies  
The finger pulse oximeter should be returned to the stie at the study exit visit. After all study tests and 
procedures have been completed and just prior to subject exit from the study, the subject may be 
informed (verbally or in written form) of the subject’s  randomization assignment.  
Following exit, subjects will continue to receive standard medical care  and should be managed and 
followed per physician discretion . There will be no further required study -related follow -up visits for these 
subjects .  
10.15.1.    Lost to Follow -Up 
In the case that the subject is determined to be lost to follow -up, details of a minimum of two attempts 
to contact [CONTACT_423], and the method of attempt (e.g., one letter and one p hone record, or two letters) 
must be recorded.  
10.15.2.    Subject Does Not Meet Eligibility Criteria  
If eligibility is not met, the subject must be exited prior to study procedures and device programming .  
10.15.3.    Subject chooses to exit (i.e. revokes informed consent)  
A subject can withdraw from the study at any time. If the subject wishes to exit from the study (i.e. the 
subject revokes informed consent), the site is required to document the reason for exit on the Study Exit 
eCRF.  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567313] in the study and perform study procedures / 
collect data to the extent possible. If an Investigator withdrawal is necessary, the site is required to 
document the reason for exit on the Study Exit eCRF.  
10.16.    Device Interrogation  / Save -to-Media  
For the Baseline , Randomization and  in clinic follow -up visits, an initial interrogation and final device 
interrogation file  (since last session)  must be obtained (.pdd) and saved in a digital format (Save -to-
Media). Store one copy of the save-to-media at the site and send a copy to Medtronic. It is recommended 
that data are not cleared d uring any interrogation.  
An initial interrogation and final device interrogation (since last session)  and Save -to-Media should also 
be completed at the tim e of study exit, for a crossover, a system modification, and in the case of a death 
(where possible).  
10.17.    System Modification  
A system modification will be reported in the event the device and/or leads require invasive modification 
(e.g. generator or  lead explant, generator or lead replacement, lead repositioning, etc.). In the event of a 
system modification, regardless of outcome of the modification, subjects should remain in the study when 
possible and the follow -up visit schedule for the subject wi ll remain unchanged. For a system modification 
the following information/activities are required to be collected:  
• Report the reason for the system modification  
• Report the details of the system modification procedure  
• Device interrogation (initial and final ) 
• Save-to-Media  (a copy of the interrogation files must be sent to Medtronic with a copy also being 
maintained at the site) 
• Report the associated AE  or Device Deficiency, if applicable  
It is recommended that all explanted Medtronic products (device, leads, etc.) are returned to Medtronic 
for analysis per local process and when permissible by [CONTACT_10976].  
In the event that subject has a re -attempt after a previous unsuccessful system modification, the 
subsequent attempt(s) must be reported via eCRF as  separate system modifications.  
10.18.    Deviation Handling  
A study deviation is defined as an event within a study that did not occur according to the Clinical 
Investigation Plan o r the Clinical Trial Agreement.  
Prior approval by [CONTACT_446155], contemplates, or 
makes a conscious decision to deviate. Prior approval is not required when a deviation is necessary to 
protect the safety, rights or well -being of a subject in an emergency or in unfore seen situations beyond 
the investigator’s control (e.g. subject failure to attend scheduled follow -up visits, inadvertent loss of data 
due to computer malfunction, inability to perform required procedures due to subject illness , blood 
sample or echo lost a t Core Lab ). 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567314]’s ability to complete a study -required 
procedure, it may be permitted to report only one deviation which will apply to all visits going forward. 
This may also apply for other unfores een situations (e.g. the subject permanently refuses to complete a 
study required procedure and the data will not contribute to the primary end point analysis). However, 
prior approval from Medtronic i s required for such situations.  
All study deviations mu st be reported to Medtronic regardless of whether they are  medically justifiable, 
pre-approved by [CONTACT_13735], an inadvertent occurrence, or taken to protect the subject in an emergency. 
The deviation must be recorded in Oracle Clinical (see  Section  10.18.    Deviation Handling ) with an 
explanation for the deviations.  
In the event the deviation involves a failure to obtain a subject’s informed consent, or is made to protect 
the life or physical well -being of a subje ct in an emergency, the deviation must be reported to the IRB as 
well as Medtronic as soon as possible but no later than five (5) working days, or according to local 
requirements.  Reporting of all other study deviations should comply with the IRB  policies  and/or local 
laws and deviations must be reported to Medtronic as soon as possible upon the site becoming aware of 
the deviation.  
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any 
additional corrective an d/or preventive actions (e.g. amend the Clinical Investigation Plan, conduct 
additional training, terminate the study). Repetitive or serious investigator compliance issues may result 
in initiation of a corrective action plan with the investigator and site , and in some cases, necessitate 
suspending enrollment until the problem is resolved or ultimately terminating the investigator's 
participation in the study. Medtronic may provide site -specific reports to investigators summarizing 
information on deviations  that occurred at the investigational site on a periodic basis.  
10.19.    Assessment of Safety  
As a feasibility study, the primary objective is to assess the feasibility of using elevated night pacing as a 
therapy for heart failure with preserved ejection fraction .  This includes  assessing the safety and 
tolerability of elevated night pacing, as described  in Section 5.1.   Background . Subjects who experience 
intolerabl e symptoms from the elevated pacing therapy and whose symptoms cannot be reconciled by 
[CONTACT_446156] .  NT-proBNP, troponin , assessed 
from peripheral blood samples  and LVEF, as assessed by [CONTACT_446157],  will be collected at Baseline and at the 
4 week visit.  Subjects with increases in NT-proBNP  and troponin from Baseline to the 4 week visit should 
be monitored by [CONTACT_446158], including worsening heart failure and 
cardiac isc hemia.  Symptoms should be reported as adverse events and subjects will be considered for 
withdrawal from the study, at the discretion of the investigator.  Subjects with 4 week LVEF < 45% 
whose baseline LVEF was at least 55% may also be considered for wit hdrawal from the study at the 
discretion of the investigator .  NT-proBNP, troponin an d LVEF  will be further  assessed as discussed in  
Section 10.11.    Randomization  (4 Week Follow -Up) and Section  14.1.2.   Ancillary Safety Endpoint – NT-
proBNP, troponin, LVEF . Further information on the collection of  Adverse Events is discussed in  Section  
12.5.   Reporting of Adverse Even ts. 
10.20.    Assessment of Efficacy  
Assessment of efficacy will be done on an exploratory basis.  Quality of life, mobility and echo 
measurements will be  collected  and assessed  as discussed in Section s 6.[ADDRESS_567315] data using Oracle Clinical, an electronic data management system for clinical 
studies. Sites will enter data onto eCRFs within an Oracle Clinical database.  
Data reported on the eCRFs shall be derived f rom source documents, which may include worksheets, 
QOL questionnaires, patient medical records , echo data, blood lab data, programmer printouts and device 
interrogation /save -to-media  files. These source documents must be created and maintained by [CONTACT_446159]. Further detail on  data management is provide d in Section  16.2.   Data 
Management .   
11.1.  Potential Risks  
Medtronic follows rigorous Quality Assurance and Control proc edures throughout the life of the product, 
from the research and development phase through the s tudy phase and market release.  
There are risks associated with the elevated night pacing:  
Table 9: Risks Related to Elevated Pacing  
Risk Potential Patient Harm  Mitigation  
Pacing at a sustained 
elevated rate that causes 
symptoms during the day 
or night  Increased risk of 
Dizziness, palpi[INVESTIGATOR_814], 
heart racing, shortness of 
breath, difficulty sleepi[INVESTIGATOR_446134], subjects 
will be evaluated to whether they 
can tolerate a pacing rate of 
100bpm  
Subjects will be instructed to call 
study team if they are experiencing 
symptoms  
Symptoms will be gathered from 
subjects using phone calls following 
enrollment, [ADDRESS_567316] s using phone calls following 
enrollment, 4 week, and 8 week 
clinic visits  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 45 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Pacing at a sustained 
elevated rate that causes 
symptoms following 
unscheduled clinic visits. 
(Any minor telemetry 
activation, such as 
reprogramming, magnet 
application, or CareLink 
transmission will suspend 
the Sleep Function and 
the pacer will start pacing 
at the programmed Lower 
Rate.)  Increased risk of 
Dizziness, palpi[INVESTIGATOR_814], 
heart racing, shortness of 
breath  Subjects will be instructed to call 
study team if they are exp eriencing 
symptoms  
Subjects will also be asked their 
heart rate, which the subject can 
read using a finger pulse oximeter 
monitor that will be given to them 
at Baseline to use  
Centers will be trained to instruct 
subjects to come to center for 
unscheduled visits 
Misleading information 
that could reasonably lead 
to incorrect pacing 
therapy. (Rate histograms 
will show a higher 
percentage of pacing at 
100bpm.  Clinicians not 
aware of the subject’s 
participation in the study 
may program the Lower 
Rate back to pre-study 
values.)  No risk to the patient.  
May result in loss of 
usable data for the study.   
Subjects will be given a REVAMP 
study ID card  
Negative impact  to device 
longevity due to change 
in the pacing rate to [ADDRESS_567317] device 
longevity by 20% over 
remaining lifetime of 
device.  Premature 
battery depletion which 
could lead to early 
Explant/ revision  
procedure related  
harm (Infection, 
Thrombus , Embolus, 
Hematoma,  
Stroke,Pneumothorax,  
Hemothorax, Nerve  
Damage)  
  The Patient informed Consent will 
include warnings about the impact to 
battery life of the device, if the patient 
does not adhere to thestudy protocol 
for the [ADDRESS_567318] (FAL) in APPENDIX C. 
Subjects who are pregnant are excluded from study participation. If a subject becomes pregnant  during 
the study, she must no tify the physician immediately.  
There may be other discomforts and  risks related to elevated night pacing and this study that are not 
foreseen at this time. The adverse event collection requirements in this study will ensure that risks 
associated with the study are adequately monitored.  
11.[ADDRESS_567319] by [CONTACT_716]:  
• Performing required laboratory and pre -clinical testing prior to the REVAMP clinical study . 
• Implementing quality control measures into development and production  processes . 
• Providing guidelines for subject selection and evaluation, and subject  inclusion and exclusion 
criteria . 
• Providing adequate instructions and  training . 
• Selecting investigators that have demonstrated previous experience with  the programming, 
interr ogation, and monitor ing of pacemaker  devices . 
• After enrollment in the REVAMP clinical s tudy, at each protocol required follow -up, the 
investigator must evaluate the subject’s health , assess for  any adverse events , and interrogate 
the study device to verify appropriate  study d evice function . 
11.3.   Potential Benefits  
Elevated pacing rates may offer no benefit. The potential benefits of having the elevated pacing ON for 
this 12 week study include:  
• Improvement in exercise capacity  
• Improvement in symptoms  
Additionally, information collected from this study may assist in the design of new product(s)/therapy(ie s) 
and/or instructions for use.  
11.4.   Risk-Benefit Rationale  
The risk for harm is minimal with this study as the pacing rate is within the FDA -approved programmabl e 
parameters of the Lower Rate and the Sleep Function , and pacing rates of [ADDRESS_567320] , as listed in Section 11.3.   Potential 
Benefits . Therefore, the study risk -benefit is acceptable . 
12.   Adverse Event Assessments  
Timely, accurate, and complete reporting and analysis of safety information for clinical studies are crucial 
for the protection of subjects. Medtronic has established procedures to ensure appropriate r eporting of 
safety information.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 47 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
  12.1.   Adverse Events  
Adverse Event definitions are provided in Table 10. To ensure that all AEs that are potentially relevant are 
collected , the following  will be collected throughout the study duration, starting at the time of signing the 
Informed C onsent  Form: 
• All system related AEs  
• All programming related AEs  
• All cardiovascular related AEs  
• All Serious Adverse Events (SAEs), regardless of relatedness  
In order to fully understand intolerable symptoms  and mitigate any safety concerns about elevated night 
pacing, for any subject that exits the study because of intolerable symptoms , the enrolling site should 
report any associated programming related AEs.  Reporting of these events to Medtronic will occu r on an 
Adverse Event (AE) eCRF. Documented pre -existing conditio ns are not considered AEs unless the nature 
or severity  of the condition has worsened.  
For AEs that require immediate reporting (see Table 12), initial reporting may be done by [CONTACT_648], fax, or 
on the eCRF completing as much information as possible. The original completed AE eCRF must be 
submitted to Medtronic as soon as possible.  
Each adverse event must be reported s eparately. Any medication, whether cardiovascular or not, 
associated with the treatment of an adverse event must be reported.  
Subject deaths are also required to be reported. Refer to Section 12.6.   Subject Death  for Subject Death 
collect ion and reporting requirements.  
12.2.   Device Deficiencies  
Device Deficiency is defined as an inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance. Device Deficiencies will need to be collected in the study. 
Device Deficiency information will be collected throughout the s tudy and reported to Medtronic.  
12.3.   Processing  Updates and Resolution  
For any changes in status of a previously reported adverse event (i.e. change in actions taken, change in 
outcome, change in relatedness), information needs to be updated on, or added to the original AE eCRF. 
All adverse events must  be followed until the adverse event has been resolved, is unresolved with no 
further actions planned, the subject dies or exits the study, or until study c losure, whichever occurs first.  
At the time of study exit, all collected adverse events with an outc ome of “Unresolved” must be reviewed 
and an update to the original AE eCRF must be reported. At a minimum, if there are no changes to the 
description, relatedness, test and procedures or actions taken, the outcome must be updated to reflect 
“Unresolved at time of study exit”.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 48 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 12.4.   Definitions/Classifications  
Where the definition indicates “device”, it refers t o any device used in the study.  
Table 10: Adverse Event and Device Deficiency Definitions  
General  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease or injury, 
or untoward clinical signs (including abnormal laboratory findings) 
in subjects, users or other persons, whether or not related to the 
investigational medical device  
 
NOTE 1: This definition inclu des events related to the 
investigational medical device or the comparator.  
NOTE 2: This definition includes events related to the procedures 
involved.  
NOTE 3: For users or other persons, this definition is restricted to 
events related to investigational m edical devices.  
(ISO [ZIP_CODE]:2011, 3.2)  
Adverse Device Effect (ADE)  Adverse event related to the use of an investigational medical 
device  
 
NOTE 1: This definition includes adverse events resulting from 
insufficient or inadequate instructions for use, deployment, 
implantation, installation, or operation, or any malfunction of the 
investigational medical device.  
NOTE 2: This definition includes any event resulting from an error 
use or from intentional misuse of the investigational medical 
device. (ISO 14 155:2011, 3.1)  
Device Deficiency (DD)  Inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety or performance.  
 
NOTE: Device deficiencies include malfunctions, use errors and 
inadequate labeling (ISO [ZIP_CODE]:201 1, 3.15)  
Relatedness  
System Related  
 
 
 An adverse event that results from the presence or performance 
of any component of the system.  
 
Device -related : An adverse event that results from the presence 
or performance (intended or otherwise) of the device.  
RA lead -related : An adverse event that results from the presence 
or performance (intended or otherwise) of the RA lead.  
RV lead -related : An adverse event that results from the presence 
or performance (intended or otherwise) of the RV lead.  
 
Programming Related  An adverse event that results from the CIP required programming 
for elevated night pacing therapy.  
Cardiovascular Related  
 
 
 
 An Adverse Event relating to the heart and the blood vessels or 
the circulation, e.g. Atrial Fibrillation, Myocardial Infarction, 
stroke, perivascular disease.  
 
 
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 49 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Seriousness  
Serious Adverse Event (SAE)  
 Adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject, that 
either resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body 
function, or  
3) in-patient or prolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical intervention to prevent life -
threatening illness or injury or permanent impairment to 
a body structure or a body functi on, 
c) led to fetal distress, fetal death or a congenital abnormality 
or birth defect  
 
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_10396], without serious deterioration in 
health, is not considered a serious ad verse event.  
(ISO [ZIP_CODE]:2011, 3.37)   
Unanticipated Adverse Device Effect 
(UADE)  
 Any serious adverse effect on health or safety or any life -
threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death, was not previously 
identified in a nature, severity, or degree of incidence in the 
investiga tional plan or application (including a supplementary plan 
or application), or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or 
welfare of subjects. (21 CFR 812.3(s))  
12.5.   Reporting of Adverse Even ts 
12.5.1.   Adverse Event and Device Deficiency Classification  
All reported Adverse Events and Device Deficiencies will be reviewed by a Medtronic representative. AEs 
will be classified according to the definitions provided.  
Upon receipt of Adverse Events  at Medtronic, a Medtronic representative will review the Adverse 
Event/Device Deficiency for completeness and accuracy and when necessary will request clarification  
and/or additional information from the Investigator. Medtronic will utilize MedDRA, the Me dical Dictionary 
for Regulatory Activities, to assign a MedDRA term for each adverse event based on the information 
provided by [CONTACT_093].  
Regulatory reporting of AEs and Device Deficiencies will be completed according to local regulatory 
requirements. Refer to Table [ADDRESS_567321] (FAL), which is a list of adverse events that 
may be experienced by [CONTACT_1766]. This list may help to assess if an adverse event is unanticipated in 
nature.  
For emergency contact [CONTACT_169280] a UADE, contact a clinical study representative immediately (refer to 
the study contact [CONTACT_181023]’s study documents binder/investigator site file or refer to the 
Sponsor Cont act Information section provided in the CIP).  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567322] definitions as outlined belo w: 
Table 11: Adverse Event Classification Responsibilities  
What is 
classified?  Who 
classifies?  Classification Parameters  
Relatedness  Investigator  Device, RA Lead, RV Lead, Programm ing, Cardiovascular  
Sponsor  Device, RA Lead, RV Lead, Programm ing 
Seriousness  Investigator  SAE  
Sponsor  SAE, UADE  
Diagnosis  Investigator  Based on presenting signs and symptoms and other 
supporting data  
Sponsor  MedDRA term assigned based on the data provided by 
[CONTACT_54437], Non -sudden Cardiac, Non -Cardiac, 
Unknown  
12.5.2.  Adverse Event and Device  Deficiency Reporting Requirements  
Regulatory reporting of AEs and device deficiencies will be recorded and reported according to local 
regulatory requirements. It is the responsibility of the Investigator to abide by [CONTACT_446160]’s IRB. 
Table 12: Reporting Requirements  
Unanticipated Adverse Device Effects (UADEs)   
Investigator submit to:  
Medtronic  Submit as soon as possible, but no later than within [ADDRESS_567323] learns of the event. (21 CFR 812.150(a)(1))  
IRB Submit as soon as possible, but no later than within [ADDRESS_567324] learns of the event. (21 CFR 812.150(a)(1))  
Sponsor submit to:  
Regulatory 
authorities   
Submit as soon as possible, but no later than within [ADDRESS_567325] 
learns of the event. (21 CFR 812.150( b)(1))  
IRB Submit as soon as possible, but no later than within [ADDRESS_567326] 
learns of the event. (21 CFR 812.150( b)(1))  
Investigators  Submit as soon as possible, but no later than within [ADDRESS_567327] 
learns of the event. (21 CFR 812.150( b)(1))  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567328] be reported by [CONTACT_446161] (AE with 
outcome of death) as soon as possible after the investigator first learns of the death.  In case of death, 
there should be on e AE with the outcome of dea th. 
In the event of a subject’s death, it is recommended that the implanted system be explanted and 
returned to Medtronic for analysis whenever possible per local process. Local laws and procedures must 
be followed where applicable.  
System Interrogation Da ta Recommendations:  
• After the subject has died but prior to explant, it is strongly recommended that the system be 
interrogated and a full summary interrogation (Interrogate All) performed when possible, and 
saved in a digital format (Save -to-Media). Store  one copy of the save -to-media at the site  and 
send a copy to Medtronic.  
• Make the device interrogation/save -to-media file before any programming to prevent overwriting 
information in the device’s memory and/or distinguishing between events detected during versus 
before the explant procedure.  
• Recommend obtaining the exact date and time of death as lower temperatures after death can 
cause ERI and other “event flags” to be stored in the device memory.  
A copy of the death certificate, if available and allowed by [CONTACT_54443]/local law, should be sent to the 
Medtronic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary report 
and all relevant hospi[INVESTIGATOR_54380], if available. If an 
autops y is conducted, the autopsy report should also be sent to the Medtronic clinical study team if 
available and allowed by [CONTACT_54443]/local law. When the death occurs at a remote site, it is the investigative 
site’s responsibility to attempt retrieval of informati on about the death. Additionally, device disposition 
information should be updated. In summary, the following data will be collected:  
• Date of death  
• Detailed description of death  
• Cause of death  
• Relatedness to system and/or procedure  
• Device interrogation an d Save -to-Media (if available)  
• Device disposition information  
• Death summary/hospi[INVESTIGATOR_1097] (if available and allowed by [CONTACT_54443]/local law)  
• Autopsy report (if available and allowed by [CONTACT_54443]/local law)  
• Death certificate (if available and allowed by [CONTACT_54443]/loc al law)  
12.6.2.  Death Classification and Reporting  
Sufficient information will be required in order to properly classify the subject’s death. The Investigator 
shall classify each subject death per the following definitions:  
Cardiac Death : A death directly  related to the electrical or mechanical dysfunction of the heart.  
Sudden Cardiac Death (SCD) : Natural death due to cardiac causes, indicated by [CONTACT_54444]; preexisting heart disease may have  been 
known to be present, but the time and mode of death are unexpected. If time of onset cannot be 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 52 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 determined, SCD will alternatively be defined as any unexpected cardiac death occurring out of the 
hospi[INVESTIGATOR_54381].  
Non-sudden Cardiac Death : All cardiac deaths that are not classified as sudden deaths, including all 
cardiac deaths of hospi[INVESTIGATOR_54382].  
Non-cardiac Death : A death not classified as a cardiac death.  
Unknown Classification : Unknown d eath classification is intended for use only when there is insufficient or 
inadequate information to classify the death.  
Table 13: Subject Death Classification Responsibilities  
What is 
classified?  Who 
classifies?  Classification Par ameters  
Relatedness  Investigator  Device, RA Lead, RV Lead, Programming  
Death Classification  Investigator  Sudden Cardiac, Non -sudden Cardiac, Non -cardiac, 
Unknown  
Regulatory reporting of Subject Deaths will be completed according to  local regulatory requirements.  
12.7.   Product Complaint Reporting  
All devices used in the study will be market released at study start. Therefore, product complaint 
reporting is applicable and AEs related to any market -released device during the study must be reported. 
The reporting of product complaints is not part of the clinical study and should be done in addition to the 
Adverse Event reporting requirements.  Refer to local r egulati ons for reporting requirements.  
Product Complaint: Any written, electronic or oral communication that alleges deficiencies related to the 
identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has 
been placed on the market.  
13.   Data Review Committees  
13.1.   Echocardiography Core Laboratory  
The study will utilize an Echocardiography Core Laboratory (echo core lab). The echo core lab will 
complete data analysis on all study echoes required to be performed ( Baseline, 4 week, 8 week, and 12 
week). An echocardiogram will be performed as described in the Echocardiography Handbook (provided 
under separate cover).   
The echo core lab will be blinded to subjects’ randomization assignment. Echoes sent to the core lab for 
analysis will be labeled in such a way to maintain the blind  and not provide information that would inform  
which visit the echo was collected . 
13.2.   Blood Core Laboratory  
The study will utilize a Blood Core Laboratory  (blood core lab) . The blood  core lab will complete data 
analysis on all study blood samples  required to be performed ( Baseline, 4 week, 8 week, and 12 week). 
Details of the blood core lab and the blood draw process will be provided under separat e cover . 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567329] with this therapy.  Figure 3 indicates that 
improvements in the confidence interval width at various propo rtions of subjects meeting the 4 week 
safety and tolerability endpo int beyond 30 subjects are relatively small.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 54 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Figure 3: 95% Confidence Interval Widths for Various Proportions of 4 Week Safety 
and Tolerability Endpoint  
 
 
C.I. Width vs N with C.L.=0.95 P=0.500 C.I. One
ProportionC.I. Width
N0.[IP_ADDRESS].300.350.40
0 10 20 30 40 50
C.I. Width vs N with C.L.=0.95 P=0.700 C.I. One
ProportionC.I. Width
N0.[IP_ADDRESS].5
0 10 20 30 40 50
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 55 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
  
This section presents statistical considerations for the study design and provides a high -level description 
of planned analysis and reporting. More details will be given in a separate Statistical Analysis Plan (SAP) 
that will be completed before data freez e and unblinding for the primary objective analysis. Any deviation 
to the pre -specified statistical analyses will be noted in the study report.  
As part of the exploratory/ancillary safety, tolerability and efficacy effects described in 10.20.    
Assessment of Efficacy , it will be of interest to characterize changes in collected measurements from 
baseline to [ADDRESS_567330] 4 weeks of the rapy were safe and tolerable.  
If there are changes in any of the efficacy measurements from baseline to week 4 and/or improvements 
in any of the efficacy measurements in the ON arm compared to the OFF arm from week 4 to week 8, 
there may be additional analyses on the extracellular matrix biomarkers to correlat e to the efficacy 
improvements.  
C.I. Width vs N with C.L.=0.95 P=0.900 C.I. One
ProportionC.I. Width
N0.[IP_ADDRESS].40.5
0 10 20 30 40 50
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 56 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 14.1.   Endpoint Definitions  
14.1.1.   Ancillary Safety and Tolerability Endpoint  
Safety and Tolerability – 4 weeks  
 
Hypothesis  
A 4 week period of elevated night pacing is safe and tolerable.   
 
Analysis Methods  
The proportion of subjects who remain in the study  up until the 4 week visit  without exiting 
due to intolerable symptoms , increase in NT -proBNP levels, decrease in LVEF or increase in 
troponin will be calculated along with the lower bound of the one -sided 95% confidence 
interval  
 
Determination of Subjects for Analysis  
All enrolled subjects that are programmed with elevated night pacing.  
 
Safety and Tolerability – 8 weeks  
 
Hypothesis  
Following a 4 week period of elevated night pacing, compare the safety and tolerability of 
subjects in the ON and OFF arm for an additional 4 weeks of elevated night pacing  
 
Analysis Methods  
The proportion of subjects who remain in the study  from the 4 week visit to the 8 week visit  
without exiting due to intolerable symptoms , increase in NT -proBNP levels, decrease in LVEF 
or increase in troponin will be calculated along with the lower bound of the one -sided 95% 
confidence interval  for both a rms (elevated night pacing left ON versus elevated night pacing 
programmed OFF).  
Determination of Subjects for Analysis  
All subjects that completed [ADDRESS_567331] 4 weeks because of safety or other 
issues will not be included in this analysis.  
14.1.2.   Ancillary Safety Endpoint – NT-proBNP, troponin, LVEF  
NT-proBNP, troponin, LVEF – 4 weeks  
 
Hypothesis  
For each of the main safety measures (NT -proBNP, troponin and LVEF) , comparisons will be 
done to see if there are changes from baseline after a [ADDRESS_567332] will be performed testing the 
hypothesis  
Ho:  = 0 
  Ha:  ≠ 0 
  Where = difference in measurement from baseline to week [ADDRESS_567333] 4 weeks because of safety or other 
issues will not be included in this efficacy analysis.  
NT-proBNP, troponin, LVEF – 8 weeks  
Hypothesis  
For each of the main safety measures (NT -proBNP, troponin and LVEF), it will be assessed 
whether there is a difference in the change of  the measurement following  an additional [ADDRESS_567334] will be performed testing the hypothesis  
Ho:  = OFF 
  Ha: ≠ OFF 
Where = difference in NT-proBNP, troponin or LVEF  from week 4 to week 8  for subjects 
in the ON arm and OFF= difference in those measurements in subjects in the OFF arm  
Determination of Subjects for Analysis  
All subjects that completed 4 weeks of elevated night pacing.  NT-proBNP, troponin or LVEF  
at time of exit will be used for subjects that do not complete the full 4 weeks of participation 
in the study from week 4 to week 8.  
14.1.3.   Ancillary Safety Endpoint – Adverse Events  
Adverse Events – [ADDRESS_567335] 4 weeks of 
elevated night pacing.  
Analysis Methods  
Summarization of adverse events by [CONTACT_6213].   Summarization may include 
pertinent subgroups, including all potentially related events and all CV -related events.  
Determination of Subjects for Analysis  
All adverse events reported for subjects actively receiving elevated night pacing will be 
included.  
Adverse Events – 8 weeks  
Hypothesis  
There are differential rates of adverse event reporting between subjects randomized to 
receive elevated night pacing and subjects randomized to elevated night pacing OFF.  In 
addtion, a dverse events for subjects continui ng to receive elevated night pacing will be 
characterized and extended from the AE’s colle cted during the first 4 weeks.  
Analysis Methods  
The adverse reporting rate during the period from week 4 to week 8 in subjects in the ON 
arm and OFF arm will be  compa red and characterized.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 58 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Determination of Subjects for Analysis  
Rates of ad verse events for subjects randomized to OFF will be calculated over the full period 
of follow -up, while rates of adverse events for subjects randomized to ON will be calculated 
only during the period that subjects were actually receiving elevated night pacing . 
14.1.4.   Ancillary Efficacy Endpoint - Quality of Life  
MNLWHF Questionnaire – [ADDRESS_567336] will be performed testing the 
hypothesis  
Ho:  ≤ 0 
  Ha:  > 0 
  Where = difference in MNLWHF score from baseline to week [ADDRESS_567337] 4 weeks  because of safety or other 
issues will not be included in this efficacy analysis.  
MNLWHF Questionnaire – [ADDRESS_567338] will be performed testing the 
hypothesis  
Ho: ≤ OFF 
  Ha:  > OFF 
  Where  = difference in MNLWHF score from week 4 to week 8  
Determination of Subjects for Analysis  
All subjects that completed 4 weeks of elevated night pacing .  MNLWHF score at time of exit 
will be used for subjects that do not complete the full  4 weeks of participation in the study 
from week 4 to week 8.  
EQ-5D-5L Questionnaire – [ADDRESS_567339] will be performed testing the 
hypothesis  
Ho:  ≤ 0 
  Ha:  > 0 
  Where = difference in EQ-5D-5L score from baseline to week [ADDRESS_567340] will be performed testing the hypothesis  
Ho: ≤ OFF 
  Ha:  > OFF 
  Where  = differ ence in EQ -5D-5L score from baseline  to week [ADDRESS_567341]  Distance – [ADDRESS_567342] will be performed testing the 
hypothesis  
Ho:  ≤ 0 
  Ha:  > 0 
  Where µ = difference in [ADDRESS_567343]  Distance  – [ADDRESS_567344] will be performed testing the hypothesis  
Ho:  ≤ OFF 
  Ha:  > OFF 
Where  = difference in MNLWHF score from week 4 to week 8  in subjects 
randomized to the ON arm and OFF  = difference in [ADDRESS_567345]  distance  at 
time of exit will be used for subjects that do not complete the full 4 weeks of participation in 
the study from week 4 to week 8.  
  
Device -measured activity levels  – [ADDRESS_567346] 4 weeks because of safety or other 
issues will not be included in this efficacy analysis.  
 
Device -measured activity levels  – 8 weeks  
Hypothesis  
There is an improvement in daytime activity levels over an additional 4 week period of 
elevated night pacing after an initial 4 week period of elevated night pacing compared to that 
period of 4 weeks with the elevated night pacing programmed OFF aft er the initial 4 weeks 
period of elevated night pacing.  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 61 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Analysis Methods  
Activity levels over time will be characterized over time from the 4 week visit to the 8 week 
visit and compared between the subjects with the elevated pacing programmed ON versus 
OFF. 
Determination of Subjects for Analysis  
All subjects that completed 4 weeks of elevated night pacing.  Daytime activity levels up to 
time of exit will be used for subjects that do not complete the full 4 weeks of participation in 
the study from week 4 to week 8.  
14.1.6.   Ancillary Efficacy Endpoint – Echo Measurements  
Echo measurements – [ADDRESS_567347] will be performed testing the 
hypothesis  
Ho:  = 0 
  Ha:  ≠ 0 
  Where = difference in measurement from baseline to week [ADDRESS_567348] 4 weeks b ecause of safety or other 
issues will not be included in this efficacy analysis.  
 
Echo measurements  – [ADDRESS_567349] will be performed testing the hypothesis  
Ho:  = OFF 
  Ha:  ≠ OFF 
Where  = difference in echo measurement  from week 4 to week 8  in subjects 
randomized to the ON arm and OFF  = difference in echo measurem ent from week 4 to 
week 8 in subjects randomized to the OFF arm  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 62 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Determination of Subjects for Analysis  
All subjects that completed 4 weeks of elevated night pacing.  Echo measurement  at time of 
exit will be used for subjects that do not complete the full 4 weeks of participation in the 
study from week 4 to week 8.  
14.1.7.   Ancillary Efficacy Endpoint – Collagen Degradation Biomarker 
Measurements  
Biomarker measurements – [ADDRESS_567350] will be performed testing the 
hypothesis  
Ho:  = 0 
  Ha:  ≠ 0 
  Where = difference in measurement from baseline to week [ADDRESS_567351] 4 weeks because of safety or other 
issues will not be included in this efficacy analysis.  
 
Biomarker measurements – [ADDRESS_567352] will be performed testing the hypothesis  
Ho:  = OFF 
  Ha:  ≠ OFF 
Where  = difference in collagen degradation biomarker  measurement  from week 4 
to week 8  in subjects randomized to the ON arm and OFF  = difference in collagen 
degradation biomarker  measurement  from week 4 to week 8 in subjects randomized to 
the OFF arm  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 63 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Determination of Subjects for Analysis  
All subjects that completed 4 weeks of elevated night pacing.  Biomarker measurement  at 
time of exit will be used for subjects that do not complete the full 4 weeks of participation in 
the study from week 4 to week 8.  
14.1.8.    Ancillary Efficacy Endpoint – Sustained effects  of elevated  night pacing  
Hypothesis  
it will be explored whether there are sustained eff ects of elevated night pacing.  
Analysis Methods  
These analyses will be exploratory in nature, involving characterizing changes f rom baseline 
and end of therapy to the last follow -up visit.  
Determination of Subjects for Analysis  
All subjects that have follow -up visits after elevated night pacing was programmed OFF.  This 
will include subjects completed 12 weeks of follow -up and subjects that had elevated night 
pacing pro grammed OFF at 4 weeks and completed 8 weeks of follow -up. 
15.   Ethics  
15.1.   Statement(s) of Compliance  
REGULATORY COMPLIANCE  
This REVAMP study will be conducted in compliance with international ethical and scientific quality 
standards, known as good c linical practice (GCP). The study was designed to reflect the GCP principles 
outlined in ISO [ZIP_CODE]:2011. GCP includes review and approval by [CONTACT_446162] a s ubject before initiating 
the study.  
The study will be conducted according to federal, national and local laws, regulations, standards, and 
requirements where the study is being conducted. The principles of the Declaration of Helsinki have been 
implemented through the patient informed consent process, IRB approval, study training, clinical trial 
registration, preclinical testing, risk -benefit assessment and publication policy.  
The REVAMP study will be conducted as a Non -Significant Risk (NSR) IDE study. The study will be 
conducted in compliance with 21 CFR Parts 11, 50, 56, 812 .2(b)(1). This study does not require an IDE 
submission to FDA.  
The study will be publicly registered prior to first enrollment in accordance with the [ADDRESS_567353] FDAAA and Declaration of Helsinki on http://www.clinicaltrials.gov  (PL 
110-85, section 810(a)).  
Approval of the CIP and CIP amendments is required from the following groups prior to any study 
procedures at a study center:  
• Medtronic  
• An Institutional Review Board at each individual study center  
Similarly, approval of subsequent revisions to the CIP is required at each study center from the above 
mentioned groups prior to implementation of the revis ed CIP at that center.  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567354] therefore be 
allowed access to the subj ects’ case histories (clinic and hospi[INVESTIGATOR_1097], and other source 
data/documentation) upon request as per the Informed Consent  Form and Authorization to Use and 
Disclose Personal Health Information/Research Authorization/other privacy language (data prot ection 
authorization) as required by [CONTACT_446163].   The principal investigator  
[INVESTIGATOR_446135]. 
Monitoring for the study will be done in accordance to the study -specific monitoring plan.  
Monitoring visits may be conducted periodically to assess site study progress, the investigator’s 
adherence to the CIP, regulatory compliance including but not limited to IRB approval and review of the 
study, maintenance of records and reports, and review o f source documents against subject eCRFs. 
Monitors review site regulatory and study compliance by [CONTACT_54450] -compliance and 
communicating those findings along with recommendations for preventative/corrective actions to site 
personnel.  Mon itors may work with study pe rsonnel to determine appropriate corrective action 
recommendations and to identify trends within the study or at a particular site.  Regulatory documents 
may be reviewed at each study site . 
Frequency of monitoring visits may be b ased upon subject enrollment, duration of the study, study 
compliance, number of adverse events, number of deviations, findings from previous monitoring visits 
and any suspected inconsistency in data that requires investigation.  
16.2.   Data Management  
Data will be collected using Oracle Clinical, an electronic data management system for clinical studies.  
CRF data will be stored in a secure, password -protected database which will be backed up nightly.  Data 
will be reviewed using programmed and manual d ata checks.  Data queries will be made available to sites 
for resolution.  Study management reports may be generated to monitor data quality and study progress.  
At the end of the study, the data will be frozen and will be retained indefinitely by [CONTACT_389407] c. 
All records and other information about subjects participating in this study will be treated as confidential. 
Data will be transferred and processed by [CONTACT_13757] a third party designated by [CONTACT_54452] a key 
coded form, unless it’s impossible to mak e it anonymous, for instance, where the subject ’s name [CONTACT_446180] . 
Procedures in the CIP require source documentation.  Source documentation will be maintained at the 
site. Source  may include worksheets, patient medical record s, echo data, programmer printouts , device 
interrogation files,  and certain  CRF fields  which  must be created and maintained by [CONTACT_446164].  
The data reported on the eCRFs shall be derived from source documents and be consistent with these  
source documents, and any discrepancies shall be explained in writing. Save -to-media  data collected at 
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567355] Access to Source Data/Documents  
The sponsor or a regulatory authority may audit or inspect the study site to evaluate the conduct of the 
study. The clinical investigator(s)/institution(s) shall allow study related monitoring, audits, IRB review 
and regulatory inspection by [CONTACT_20618]/documents.  
16.4.   Confidentiality  
All records a nd other information abo ut subjects participating in this study will be treated as confidential. 
See Section 16.2.   Data Management  for further information.  
16.5.   CIP Amendments  
Approval of subsequent revisions to the CIP is required at each study site from the following groups prior 
to implementation of the revised CIP at the site:  
• Medtronic  
• Principal Investigators (where required by [CONTACT_1769])  
• An independent institutional review board.  
If a CIP amendment occurs, site personnel will need to be re -trained as necessary , and will need to 
submit any changes to their IRB. 
16.6.   Warranty/Insurance Information  
16.6.1.   Warranty  
Warranty information is provided in t he product packaging for the commercially released pacemaker  
devices and leads, and additional copi[INVESTIGATOR_54398].  
16.7.    Record Retention  
16.7.1.   Investigator Records  
The investigator is responsible for the preparation and retention of the records including, but not limited 
to, those cited below. All of the below records, with the exception of case history records and case report 
forms, should be kept in the Investigato r Site File (i.e., the study binder provided to the investigator) or 
Subject Study Binder. eCRFs must be maintained and signed electronically by [CONTACT_446165]. The following records are subject t o inspection and must 
be retained for a period of two years (or longer as local law/regulation or hospi[INVESTIGATOR_446136]) after product approval. Measures shall be taken to avoid loss or premature destruction.  
• All correspondence between the IRB, sponsor, monitor, and/or the investigator that pertains to 
the investigati on, including required reports.  
• Subject’s case history records, including:  
o Signed and dated Informed Consent Form, in acc ordance with local requirements  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 66 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 o Observations of adverse events/adverse device effects/device deficiencies  
o Medical history  
o Baseline and follow -up data (if applicable)  
o Documentation of the dates and rationale for any deviation from the protocol  
• Electronically signed and date d eCRFs and a blank set of eCRFs where required by [CONTACT_1769]  
• All approved versions of the CIP  and IC  Form 
• Signed and dated Clinical Trial Agreement  or Work Order  
• IRB approval documentation. Written information that the investigator or other study staff, when 
member of the IRB, did not participate in the approval process. Approval documentation must 
include the IRB c omposition, where required per local law.   
• List of investigation sites  
• Randomization list  
• Current curriculum vitae of principal investigators  
• Documentation of del egated tasks  
• Study training records for site staff   
• Final Study Report inc luding the statistical analysis  
16.7.2.   Investigator Reports  
The investigator is responsible to prepare and submit the following complete, accurate, and timely 
reports:  
Table 14: Investigator Reports for the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Unanticipated 
adverse device 
effects  Sponsor and 
IRB/MEC  The investigator shall submit to the sponsor and reviewing 
IRB as soon as possible, but no later than [ADDRESS_567356]. (21 CFR 
812.150 (a)(1))  
Withdrawal of 
IRB/MEC approval 
(either suspension or 
termination)  Sponsor  The investigator must report a withdrawal of approval by 
[CONTACT_3488]/MEC of the investigator’s part of the 
investigation within 5 working days. (21 CFR 
812.150(a)(2))  
Failure to obtain 
informed consent  IRB Investigator’s report will be submitted to  IRB within five 
working days of notification.  (21 CFR 812.150(a)(5))  
Other  IRB/MEC and FDA  An investigator shall, upon request by a reviewing 
IRB/MEC, FDA or any other regulatory agency, provide 
accurate, complete, and current information about any 
aspect of the investigation. (21 CFR 812.150(a)(7))  
 
Reports are subject to inspection and to the retention requirements as described above for investigator 
records.  
Investigator reporting requirements for safety data are listed in Section  12.   Adverse Event Assessments . 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 67 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 16.7.3.   Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records that includ es, but is not 
limited to:  
• All correspondence which pertains to the clinical study  
• Executed Clinical Trial Agreement  
• Randomization List  
• Current curriculum vitae of principal investigators  
• Electronically signed and dated eCRFs  
• All approved informed consent  templates, and other information provided to the subjects and 
advertisements, including translations  
• Copi[INVESTIGATOR_446137]/roster/letter of assurance  
• Names of the institutions in which the c linical study will be conducted  
• Names/contact [CONTACT_54459]  
• Monitoring reports (interim monitoring visit reports, follow -up letters and close -out visit reports)  
• Site qualification visit reports  
• Statistical analyses and underlying supporting data  
• Final report of the clinical study  
• The approved Clinical Investigation Plan, study related reports, and revisions  
• Documentation of delegated tasks  
• Study training records for site personnel and Medtronic personnel involved in the study  
• Sample of CRFs  
• Any othe r records that local regulatory agencies require to be maintained  
16.7.4.   Sponsor Reports  
Medtronic shall prepare and submit the following complete, accurate, and timely reports listed in the 
tables below . In addition to the reports listed below, Medtronic shall, upon request of reviewing IRB or 
FDA, provide accurate, complete and current information about any aspect of the clinical study. Safety 
data Medtronic reporting requirements are listed in Section 12.   Adverse Event Assessments . 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 68 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
  
Table 15: Sponsor R eports for the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Withdrawal of IRB 
approval  Investigators, IRB 
 Notification within five working days  after receipt of the 
withdrawal of approval .  (21 CFR 812.150(b)(2))   
Progress Reports  IRB 
 Progress reports will be submitted at least annually.  (21 
CFR 812.150(b)(5),  812.36(f)   
Failure to obtain 
informed consent  MDT, IRB Investigator’s report will be submitted to IRB within five 
working days of notification.  (21 CFR 812.150(b)(8))  
Final report  Investigators and  
IRB A final report will be submitted to investigators, and 
IRBs/MECs within six months after completion or 
termination of this study.  (21 CFR 812.150(b)(7))  
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation 
Plan are reviewed with the appropriate clinical 
investigator(s), are reported on the case report forms and 
the final report of the clinical investigation.  
Site specific study deviations will be su bmitted to 
investigators periodically.   
 
Medtronic records and reports will be maintained in a password -protected document management 
system, and paper documents (where applicable) will be stored in secured file cabinets at Medtronic 
during the course of  this study. After closure of the study Medtronic will archive records and reports as 
required by [CONTACT_5279].  
16.8.   Publication and Use of Information  
Publications from the REVAMP  clinical study will be handled according to Medtronic Policies and Standard 
Operating Procedures and as indicated in the Clinical Trial Agreement  or Work Order . 
16.8.1.   Publication Committee  
The REVAMP clinical study will utilize a Publication Committee which will include the Steering Committee 
members as well as Medtronic personnel. This committee will manage study publications with the goal of 
publishing findings from the data. The Publication Committe e may develop the final Publication Plan as a 
separate document.  
The Publ ication Committee’s role is to:  
• manage elements addressed in the publication plan as outlined in this section  
• develop the final Publication Plan under separate cover , as needed  
• execute the Publication Plan  
• oversee the publication of primary, secondary and ancillary study results  
• review and prioritize publication proposals  
• provide input on publication content, and  
• determine authorship  
In addition, the committee will apply and rei nforce the authorship guidelines set forth in the Publication 
Plan. Membership in the Publication Committee does not guarantee authorship. The committee will meet 
as needed.  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 69 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 16.8.2.   Management of Primary, Secondary, and Ancillary Publications  
The Publica tion Committee reviews, prioritizes and manages all publications including primary, secondary 
and ancillary publications. Primary and secondary publications are those that address analyses of any or 
all primary objectives or secondary/ancillary objectives,  respectively, as specified in the Clinical 
Investigation Plan. An ancillary publication is any publication that does not address the study objectives 
identified in the Clinical Investigation Plan. They include publications proposed and developed by [CONTACT_131502], clinicians participating in th is clinical study and clinicians not 
participating in this clinical study. The committee will work with Medtronic to ensure that requests do not 
present conflicts with other proposals, are no t duplicative and to determine which ancillary publication 
proposals, if any, will be supported.  
The committee may decide that no publications, including abstracts, will be published prior to the end of 
the study or with individual site data. Requests for publications on study objectives utilizing subset data 
(e.g., regional) will be evaluated for scientific validity and the ability of Medtronic to provide resources.  
16.8.3.   Criteria for Determining Authorship  
Publications will adhere to authorship criteria defined by [CONTACT_446166] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, www.icmje.org).  
Individual authorship criteria defined by [CONTACT_446167].  
Authors, including Medtronic personnel, must at a minimum meet all of the conditions below:  
• Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of data  
• Drafti ng the article or revising it critically for important intellectual content  
• Final approval of the version to be published  
Decisions regarding authorship and contributor -ship will be made by [CONTACT_446168]. The 
selected authors will be responsible for drafting the publication. All selected authors must fulfill the 
authorship conditions stated above to be listed as authors, and all contributors who fulfill the conditions 
must be listed as authors.  
All investigators not listed as co -author s will be acknowledged as the “Medtronic REVAMP  Clinical  Study 
Investigators” and will be individually listed according to the guidelines of the applicable scientific journal 
when possible. Any other contributors will be acknowledged by [CONTACT_446169].  
16.8.4.   Transparency  
Transparency of study results will be maintained by [CONTACT_54465]:  
• a final report, describing the results of all objectives and analysis, will be d istributed to all 
investigators and  IRBs. 
• registering and posting the study results on ClinicalTrials.gov based on the posting rules 
stipulated  
• submitting for publication the primary study results after the study ends  
• disclosing conflicts of interest (e.g. financial) of the co -authors of publica tions according to the 
policies set forth by [CONTACT_54466]  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 70 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 • making an individual sites study data accessible to the corresponding investigator after the 
completion of the study, if requested  
16.9.    Suspension or Early Termina tion 
16.9.1.   Planned Study Closure  
Study Closure is a process initiated by [CONTACT_57661] a study closure letter. Study closure is defined as 
closure of a clinical study that occurs when Medtronic and/or regulatory requirements have been satisfied 
per the Clinical Investigation Plan and/or by a decision by [CONTACT_131488], whichever 
occurs first. The study closure process is complete upon distribution of the Final Report or after final 
payments, whichever occurs last. Ongoing IRB oversight is required until the overall study closure 
process is complete. Upon study closure, subjects should be managed and followed per physician 
discretion.  
16.9.2.   Early Termination or Suspension  
Early Termination of the Study is the closure of a c linical study that occurs prior to meeting defined 
endpoints. This is possible for the whole study or a single site. Study Suspension is a temporary 
postponement of study activities related to enrollment and distribution of the product. This is possible fo r 
the whole study or a single site. In the event the whole study or a single site is terminated, subjects will 
be exited .  
Study -Wide Termination or Suspension  
Possible reasons for considering study suspension or termination of the study include but are no t limited 
to: 
• Adverse events associated with the system or product under investigation which might endanger 
the safety or welfare of the subject  
• Observed/suspected performance different from the product’s design intent  
• Decision by [CONTACT_446170]/Site Termination or Suspension  
Possible reasons for clinical investigator or site termination or suspension include but are not limited to:  
• Failure to obtain initial IRB approval or annual renewal of the study  
• Persistent non -compliance to the clinical investigation (e.g. failure to adhere to 
inclusion/exclusion criteria, failure to follow subjects per scheduled follow -ups)  
• Lack of enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial Agree ment or Work Order  (e.g. 
failure to submit data in a timely manner, failure to follow -up on data queries and monitoring 
findings in a timely manner, etc.)  
• IRB suspension of the site  
• Fraud or fraudulent misconduct is discovered (as define d by [CONTACT_446171])  
• Investigator request (e.g. no longer able to support the study)  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 71 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 16.9.3.   Procedures for Termination or Suspension  
Medtronic -Initiated and Regulatory Authority -Initiated  
• Medtronic will promptly inform the clinical investigators of the (early) termination or suspension 
and the reasons and inform the regulatory authority(ies) where required  
• In the case of study termination or suspension for reasons other than a temporary IRB approval 
lapse, the investigator will promptly inform the IRB  
• In the case of study termination, the investigator must inform the subjects and may inform the 
personal physician of the subjects to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subject enrollment must stop until the suspension is lifted by 
[CONTACT_13735]  
• In the case of a study suspension, enrolled subjects should continue to be followed out of 
consideration of their safety, rights and welfare  
Investigator -Initiated  
• The investigator will inform Medtronic and provide a detailed written explanation of the 
termination or suspension  
• The investigator will promptly inform the institution (where required per regulatory requirements)  
• The investigator will promptly inform the IRB 
• The investigator will promptly inform the subjec ts and/or the personal physician of the subjects 
to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subjects enrolled should continue to be followed out of 
consideration of their safety, rights and welfare  
IRB-Initiated  
• The investigator will inform Medtronic and provide a detailed written explanation of the 
termination or suspension within 5 business days  
• Subject enrollment must stop until the suspension is lifted  
• Subjects already enrolled should continue to be followed in accordance with IRB policy or its 
determination that an overriding safety concern or ethical issue is involved  
• The investigator will inform his/her institution (where required per local requirements)  
• The investigator will promptly inform the subjects, and/or the personal physician of the subjects, 
with the rationale for the study termination or suspension  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 72 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 17.   Appendices  
APPENDIX A: DATA COLLECTION ELEMENTS (ELECTRONIC CASE REPORT FORMS)  
Electronic Case Report Forms fo r the REVAMP clinical study will be provided under separate cover. Final 
eCRFs will be provided to sites via the electronic data management system after the site has fulfilled all 
requirements for database access.  
 
APPENDIX B: INFORMED CONSENT TEMPLATE(S)  
Informed Consent Form templates will be provided under separate cover.  
 
APPENDIX C: FORESEEABLE ADVERSE EVENT LIST  
The information provided in this section pertains to foreseeable adverse events  that may be observed in 
the REVAMP Study  and may assist in identifying those events that are unexpected in nature. Potential 
risks and associate d adverse e vents related to the patients implanted market -released device are in 
alignment with the product labeling. T his secti on address in more detail  those events that are foreseeable 
due to participation in the REVAMP Study in those patients with a dual chamber pacemaker .    
 
Potential risks associated with elevated night pacing as well as risk minimization  are discussed  within 
Section 11 .  Treatment required for programming related  adverse events may include device 
reprogramming, medications, or other surgical and medical remedies.  The foreseeable adverse event 
information includes rates of adverse events reported from previous Medtronic studies evaluating 
traditional pacemaker systems.  Evaluation of potentially anticipated events may involve data in this 
Clinical Investigation Plan  as well as a thorough review of all available information (e.g. labeling, current 
event reporting, published data, etc.).   
 
Adverse Events Reported in Previous Clinical Studies with Dual Chamber Pacing Systems  
 
Table [ADDRESS_567357] -market study.  
These six studies collected all adverse events and include data from 2667  subjects that underwent a 
device implant.  The average follow -up time across the six studies ranged from 5.9 to 30.8 months.  
Table 16 displays the ad verse event rates classified as related to the implanted system and/or procedure.    
Kaplan -Meier estimates and associated 95% confidence intervals of the adverse e vent rates are provided 
in the t able below at 30 -days and 12 -months (365 days) post -implant to characterize both peri -
procedural and long -term adverse events related to the procedure or implanted system.  
 
Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567358] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
ADVERSE DRUG REACTION  9 (9, 0.34%)  0.18% - 0.65%  10 (10, 0.39%)  0.21% - 0.72%  
ADVERSE DRUG REACTION  9 (9, 0.34%)  0.18% - 0.65%  10 (10, 0.39%)  0.21% - 0.72%  
AIR EMBOLISM  4 (4, 0.15%)  0.06% - 0.40%  4 (4, 0.15%)  0.06% - 0.40%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 73 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567359] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
AIR EMBOLISM  4 (4, 0.15%)  0.06% - 0.40%  4 (4, 0.15%)  0.06% - 0.40%  
ANAEMIA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
ANEMIA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
ANXIETY  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
ANXIETY  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
ATELECTASIS  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
ATELECTASIS  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
ATRIAL FIBRILLATION  59 (59, 2.25%)  1.75% - 2.90%  63 (63, 2.43%)  1.90% - 3.10%  
ATRIAL FIBRILLATION  54 (54, 2.06%)  1.58% - 2.68%  57 (57, 2.18%)  1.69% - 2.82%  
PAROXYSMAL ATRIAL FIBRILLATION  5 (5, 0.19%)  0.08% - 0.46%  6 (6, 0.25%)  0.11% - 0.55%  
ATRIAL FLUTTER  9 (9, 0.35%)  0.18% - 0.66%  9 (9, 0.35%)  0.18% - 0.66%  
ATRIAL FLUTTER  8 (8, 0.31%)  0.15% - 0.61%  8 (8, 0.31%)  0.15% - 0.61%  
PAROXYSMAL ATRIAL FLUTTER  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
ATRIAL TACHYCARDIA  11 (11, 0.42%)  0.23% - 0.76%  11 (11, 0.42%)  0.23% - 0.76%  
ATRIAL TACHYCARDIA  11 (11, 0.42%)  0.23% - 0.76%  11 (11, 0.42%)  0.23% - 0.76%  
ATRIOVENTRICULAR BLOCK FIRST 
DEGREE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
ATRIOVENTRICULAR BLOCK FIRST DEGREE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
BASILAR MIGRAINE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
BASILAR MIGRAINE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
CARDIAC FAILURE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.31%  
DECOMPENSATED HEART FAILURE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.31%  
CARDIAC FAILURE CONGESTIVE  13 (11, 0.42%)  0.23% - 0.76%  17 (15, 0.61%)  0.37% - 1.02%  
CONGESTIVE HEART FAILURE  13 (11, 0.42%)  0.23% - 0.76%  17 (15, 0.61%)  0.37% - 1.02%  
CARDIAC PERFORATION  14 (14, 0.53%)  0.31% - 0.89%  15 (15, 0.58%)  0.35% - 0.96%  
CARDIAC PERFORATION  14 (14, 0.53%)  0.31% - 0.89%  15 (15, 0.58%)  0.35% - 0.96%  
CARDIAC TAMPONADE  5 (5, 0.19%)  0.08% - 0.45%  5 (5, 0.19%)  0.08% - 0.45%  
CARDIAC TAMPONADE  5 (5, 0.19%)  0.08% - 0.45%  5 (5, 0.19%)  0.08% - 0.45%  
CARDIOMYOPATHY  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.31%  
CARDIOMYOPATHY  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.31%  
CAROTID ARTERY DISEASE  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
CAROTID ARTERY DISEASE  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
CELLULITIS  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.31%  
CELLULITIS  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.31%  
CHEST DISCOMFORT  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
CHEST PRESSURE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 74 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567360] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
CHEST PAIN  11 (10, 0.38%)  0.20% - 0.71%  14 (13, 0.52%)  0.30% - 0.90%  
CHEST PAIN  11 (10, 0.38%)  0.20% - 0.71%  12 (11, 0.42%)  0.23% - 0.76%  
RETROSTERNAL PAIN  0 (0, 0%) -- 1 (1, 0.06%)  0.01% - 0.42%  
THORACIC PAIN  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
CHRONOTROPIC INCOMPETENCE  3 (3, 0.12%)  0.04% - 0.36%  4 (4, 0.16%)  0.06% - 0.42%  
CHRONOTROPIC INCOMPETENCE  3 (3, 0.12%)  0.04% - 0.36%  4 (4, 0.16%)  0.06% - 0.42%  
COMPLICATION OF DEVICE INSERTION  17 (17, 0.64%)  0.40% - 1.02%  17 (17, 0.64%)  0.40% - 1.02%  
COMPLICATION OF DEVICE INSERTION  17 (17, 0.64%)  0.40% - 1.02%  17 (17, 0.64%)  0.40% - 1.02%  
CONFUSIONAL STATE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
CONFUSION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
CORONARY ARTERY DISEASE  11 (11, 0.42%)  0.23% - 0.76%  11 (11, 0.42%)  0.23% - 0.76%  
CORONARY ARTERY DISEASE  11 (11, 0.42%)  0.23% - 0.76%  11 (11, 0.42%)  0.23% - 0.76%  
DEVICE CAPTURING ISSUE  16 (16, 0.61%)  0.37% - 0.99%  22 (22, 0.90%)  0.59% - 1.36%  
LOSS OF CAPTURE  16 (16, 0.61%)  0.37% - 0.99%  22 (22, 0.90%)  0.59% - 1.36%  
DEVICE COMPUTER ISSUE  4 (4, 0.15%)  0.06% - 0.41%  9 (7, 0.28%)  0.13% - 0.59%  
INAPPROPRIATE DEVICE PROGRAMMING  4 (4, 0.15%)  0.06% - 0.41%  9 (7, 0.28%)  0.13% - 0.59%  
DEVICE CONNECTION ISSUE  5 (5, 0.19%)  0.08% - 0.46%  5 (5, 0.19%)  0.08% - 0.46%  
CONNECTOR BLOCK PROBLEM  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
INADEQUATE LEAD CONNECTION  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
DEVICE DAMAGE  5 (5, 0.19%)  0.08% - 0.45%  5 (5, 0.19%)  0.08% - 0.45%  
CATHETER DAMAGE  5 (5, 0.19%)  0.08% - 0.45%  5 (5, 0.19%)  0.08% - 0.45%  
DEVICE DISLOCATION  63 (59, 2.26%)  1.75% - 2.91%  84 (78, 3.06%)  2.46% - 3.81%  
DEVICE MIGRATION  0 (0, 0%)  -- 2 (2, 0.08%)  0.02% - 0.32%  
LEAD DISLODGEMENT  63 (59, 2.26%)  1.75% - 2.91%  82 (76, 2.98%)  2.39% - 3.72%  
DEVICE EXTRUSION  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
DEVICE PROTRUSION  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
DEVICE INTOLERANCE  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.32%  
DEVICE INTOLERANCE  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.32%  
DEVICE ISSUE  4 (3, 0.12%)  0.04% - 0.36%  4 (3, 0.12%)  0.04% - 0.36%  
DEVICE ISSUE  4 (3, 0.12%)  0.04% - 0.36%  4 (3, 0.12%)  0.04% - 0.36%  
DEVICE LEAD DAMAGE  2 (2, 0.07%)  0.02% - 0.30%  3 (3, 0.13%)  0.04% - 0.39%  
DEVICE LEAD DAMAGE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
DEVICE LEAD FRACTURE  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.36%  
LEAD INSULATION FAILURE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
DEVICE MALFUNCTION  2 (2, 0.07%)  0.02% - 0.30%  3 (3, 0.12%)  0.04% - 0.37%  
DEVICE MALFUNCTION  2 (2, 0.07%)  0.02% - 0.30%  3 (3, 0.12%)  0.04% - 0.37%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 75 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567361] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
DEVICE PACING ISSUE  27 (25, 0.95%)  0.65% - 1.41%  63 (57, 2.41%)  1.86% - 3.12%  
ELEVATED PACING THRESHOLD  27 (25, 0.95%)  0.65% - 1.41%  63 (57, 2.41%)  1.86% - 3.12%  
DEVICE POWER SOURCE ISSUE  0 (0, 0%)  -- 3 (3, 0.12%)  0.04% - 0.39%  
DEVICE POWER SOURCE ISSUE  0 (0, 0%)  -- 3 (3, 0.12%)  0.04% - 0.39%  
DEVICE STIMULATION ISSUE  14 (14, 0.53%)  0.32% - 0.90%  19 (17, 0.66%)  0.41% - 1.06%  
INAPPROPRIATE DEVICE STIMULATION OF 
MUSCLE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
INAPPROPRIATE EXTRA -CARDIAC DEVICE 
STIMULATION  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
INAPPROPRIATE PECTORAL MUSCLE 
STIMULATION  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.33%  
INAPPROPRIATE PHRENIC NERVE 
STIMULATION  5 (5, 0.19%)  0.08% - 0.46%  7 (7, 0.27%)  0.13% - 0.57%  
INAPPROPRIATE STIMULATION OF 
DIAPHRAGM  7 (7, 0.27%)  0.13% - 0.56%  8 (7, 0.27%)  0.13% - 0.56%  
DIARRHOEA  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
DIARRHEA  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
DIZZINESS  4 (4, 0.15%)  0.06% - 0.41%  7 (7, 0.29%)  0.14% - 0.62%  
DIZZINESS  4 (4, 0.15%)  0.06% - 0.41%  7 (7, 0.29%)  0.14% - 0.62%  
DRESSLER'S SYNDROME  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
DRESSLER'S SYNDROME  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
DYSPNOEA  1 (1, 0.04%)  0.01% - 0.28%  3 (3, 0.12%)  0.04% - 0.38%  
DYSPNEA  1 (1, 0.04%)  0.01% - 0.28%  3 (3, 0.12%)  0.04% - 0.38%  
ECCHYMOSIS  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
ECCHYMOSIS  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
EJECTION FRACTION DECREASED  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.36%  
EJECTION FRACTION DECREASED  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.36%  
ERYTHEMA MIGRANS  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
ERYTHEMA CHRONICUM MIGRANS  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
EXTRAVASATION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
EXTRAVASATION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
FALL  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
FALL 1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
FATIGUE  2 (2, 0.08%)  0.02% - 0.31%  3 (3, 0.12%)  0.04% - 0.37%  
FATIGUE  2 (2, 0.08%)  0.02% - 0.31%  3 (3, 0.12%)  0.04% - 0.37%  
HAEMATOMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HEMATOMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HAEMOGLOBIN DECREASED  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 76 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567362] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
HEMOGLOBIN DECREASED  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HEART RATE INCREASED  0 (0, 0%)  -- 2 (2, 0.08%)  0.02% - 0.33%  
HEART RATE HIGH  0 (0, 0%)  -- 2 (2, 0.08%)  0.02% - 0.33%  
HEART RATE IRREGULAR  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HEART RATE IRREGULAR  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HEPARIN -INDUCED THROMBOCYTOPENIA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HEPARIN -INDUCED THROMBOCYTOPENIA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
HYPERTENSION  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
HYPERTENSION  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
HYPOTENSION  7 (7, 0.27%)  0.13% - 0.56%  7 (7, 0.27%)  0.13% - 0.56%  
HYPOTENSION  7 (7, 0.27%)  0.13% - 0.56%  7 (7, 0.27%)  0.13% - 0.56%  
IMPAIRED HEALING  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
WOUND HEALING DELAYED  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
IMPLANT SITE DISCHARGE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
IMPLANT SITE DISCHARGE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
IMPLANT SITE HAEMATOMA  21 (21, 0.80%)  0.52% - 1.22%  23 (23, 0.88%)  0.59% - 1.32%  
IMPLANT SITE HEMATOMA  21 (21, 0.80%)  0.52% - 1.22%  23 (23, 0.88%)  0.59% - 1.32%  
IMPLANT SITE INFECTION  18 (18, 0.69%)  0.44% - 1.10%  27 (26, 1.01%)  0.69% - 1.48%  
IMPLANT SITE INFECTION  7 (7, 0.27%)  0.13% - 0.56%  9 (8, 0.31%)  0.15% - 0.62%  
IMPLANT SITE POCKET INFECTION  11 (11, 0.42%)  0.23% - 0.76%  18 (18, 0.70%)  0.44% - 1.11%  
IMPLANT SITE PAIN  9 (9, 0.35%)  0.18% - 0.66%  19 (19, 0.81%)  0.51% - 1.27%  
IMPLANT SITE PAIN  2 (2, 0.08%)  0.02% - 0.30%  3 (3, 0.12%)  0.04% - 0.36%  
IMPLANT SITE POCKET PAIN  7 (7, 0.27%)  0.13% - 0.57%  16 (16, 0.69%)  0.42% - 1.13%  
IMPLANT SITE PARAESTHESIA  0 (0, 0%)  -- 3 (3, 0.12%)  0.04% - 0.38%  
IMPLANT SITE PARAESTHESIA  0 (0, 0%)  -- 3 (3, 0.12%)  0.04% - 0.38%  
IMPLANT SITE SWELLING  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
IMPLANT SITE SWELLING  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
IMPLANT SITE WARMTH  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
IMPLANT SITE WARMTH  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
INCISION SITE COMPLICATION  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
INCISION SITE INFLAMMATION  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
INCISION SITE ERYTHEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
INCISION SITE ERYTHEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
INCISION SITE HAEMORRHAGE  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
INCISION SITE BLEEDING  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
INCISION SITE PAIN  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.32%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 77 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567363] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
INCISION SITE PAIN  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.32%  
INCISIONAL DRAINAGE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
INCISIONAL DRAINAGE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
INFECTION  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.32%  
INFECTION  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.32%  
INTENTIONAL DEVICE MISUSE  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.35%  
INAPPROPRIATE DEVICE THERAPY FOR 
ATRIAL ARRHYTHMIA  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.35%  
INTRACARDIAC THROMBUS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
INTRACARDIAC THROMBUS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
JOINT RANGE OF MOTION DECREASED  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
JOINT RANGE OF MOTION DECREASED  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
LEAD DISLODGEMENT  7 (6, 0.23%)  0.10% - 0.51%  15 (14, 0.56%)  0.33% - 0.94%  
LEAD DISLODGEMENT  7 (6, 0.23%)  0.10% - 0.51%  15 (14, 0.56%)  0.33% - 0.94%  
LOSS OF CONSCIOUSNESS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
LOSS OF CONSCIOUSNESS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
MEDICAL DEVICE DISCOMFORT  3 (2, 0.08%)  0.02% - 0.30%  3 (2, 0.08%)  0.02% - 0.30%  
MEDICAL DEVICE DISCOMFORT  3 (2, 0.08%)  0.02% - 0.30%  3 (2, 0.08%)  0.02% - 0.30%  
MEDICAL DEVICE SITE REACTION  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
TISSUE BREAKDOWN ASSOCIATED WITH 
DEVICE  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.29%  
MUSCULOSKELETAL PAIN  3 (3, 0.11%)  0.04% - 0.35%  4 (4, 0.15%)  0.06% - 0.41%  
SHOULDER PAIN  3 (3, 0.11%)  0.04% - 0.35%  4 (4, 0.15%)  0.06% - 0.41%  
MYOCARDIAL INFARCTION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
MYOCARDIAL INFARCTION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NAUSEA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NAUSEA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NECK PAIN  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
NECK PAIN  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
NIPPLE PAIN  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NIPPLE PAIN  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NON -CARDIAC CHEST PAIN  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
NON-CARDIAC CHEST PAIN  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
OEDEMA  6 (6, 0.23%)  0.10% - 0.51%  6 (6, 0.23%)  0.10% - 0.51%  
EDEMA  6 (6, 0.23%)  0.10% - 0.51%  6 (6, 0.23%)  0.10% - 0.51%  
ORTHOSTATIC HYPOTENSION  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
ORTHOSTATIC HYPOTENSION  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 78 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567364] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
POSTURAL HYPOTENSION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
OVERSENSING  0 (0, 0%)  -- 4 (4, 0.18%)  0.07% - 0.48%  
OVERSENSING  0 (0, 0%)  -- 4 (4, 0.18%)  0.07% - 0.48%  
PACEMAKER GENERATED ARRHYTHMIA  3 (3, 0.11%)  0.04% - 0.35%  4 (4, 0.16%)  0.06% - 0.42%  
PACEMAKER MEDIATED TACHYCARDIA  3 (3, 0.11%)  0.04% - 0.35%  4 (4, 0.16%)  0.06% - 0.42%  
PACEMAKER SYNDROME  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PACEMAKER SYNDROME  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PAIN  1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.31%  
PAIN 1 (1, 0.04%)  0.01% - 0.27%  2 (2, 0.08%)  0.02% - 0.31%  
PAIN IN EXTREMITY  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
PAIN IN ARM  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
PAIN OF EXTREMITIES  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PALPI[INVESTIGATOR_202909]  10 (10, 0.38%)  0.21% - 0.71%  12 (12, 0.48%)  0.27% - 0.85%  
HEART RACING  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PALPI[INVESTIGATOR_202909]  9 (9, 0.35%)  0.18% - 0.66%  11 (11, 0.44%)  0.24% - 0.80%  
PANIC ATTACK  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PANIC ATTACK  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PERICARDIAL EFFUSION  18 (17, 0.65%)  0.40% - 1.04%  20 (19, 0.73%)  0.46% - 1.14%  
CARDIAC PERFORATION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PERICARDIAL  EFFUSION  17 (16, 0.61%)  0.37% - 0.99%  19 (18, 0.69%)  0.43% - 1.09%  
PERICARDITIS  4 (4, 0.15%)  0.06% - 0.41%  5 (4, 0.15%)  0.06% - 0.41%  
PERICARDITIS  4 (4, 0.15%)  0.06% - 0.41%  5 (4, 0.15%)  0.06% - 0.41%  
PLEURAL EFFUSION  11 (11, 0.42%)  0.23% - 0.75%  11 (11, 0.42%)  0.23% - 0.75%  
PLEURAL EFFUSION  11 (11, 0.42%)  0.23% - 0.75%  11 (11, 0.42%)  0.23% - 0.75%  
PNEUMONIA  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
PNEUMONIA  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
PNEUMOTHORAX  43 (43, 1.62%)  1.20% - 2.18%  43 (43, 1.62%)  1.20% - 2.18%  
PNEUMOTHORAX  43 (43, 1.62%)  1.20% - 2.18%  43 (43, 1.62%)  1.20% - 2.18%  
POSTOPERATIVE WOUND COMPLICATION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
POSTOPERATIVE WOUND COMPLICATION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
POSTOPERATIVE WOUND INFECTION  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.39%  
SUTURE LINE INFECTION  0 (0, 0%)  -- 1 (1, 0.05%)  0.01% - 0.39%  
PRESYNCOPE  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
NEAR SYNCOPE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
VASOVAGAL REACTION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PRURITIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 79 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567365] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
PRURITIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PULMONARY EMBOLISM  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PULMONARY EMBOLUS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PULMONARY OEDEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PULMONARY EDEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
PYREXIA  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
FEVER  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
RASH  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
RASH  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
RENAL FAILURE  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
RENAL INSUFFICIENCY  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
RESTLESSNESS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
RESTLESSNESS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
SINUS TACHYCARDIA  1 (1, 0.04%)  0.01% - 0.27%  3 (3, 0.13%)  0.04% - 0.42%  
SINUS TACHYCARDIA  1 (1, 0.04%)  0.01% - 0.27%  3 (3, 0.13%)  0.04% - 0.42%  
SUBCLAVIAN ARTERY STENOSIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
SUBCLAVIAN ARTERY STENOSIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
SUBCLAVIAN VEIN THROMBOSIS  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
SUBCLAVIAN VEIN THROMBOSIS  1 (1, 0.04%)  0.01% - 0.28%  1 (1, 0.04%)  0.01% - 0.28%  
SUBCUTANEOUS EMPHYSEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
SUBCUTANEOUS EMPHYSEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
SUPRAVENTRICULAR EXTRASYSTOLES  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
PREMATURE ATRIAL CONTRACTION  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
SUPRAVENTRICULAR TACHYCARDIA  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
SUPRAVENTRICULAR TACHYCARDIA  3 (3, 0.11%)  0.04% - 0.35%  3 (3, 0.11%)  0.04% - 0.35%  
SUTURE RELATED COMPLICATION  1 (1, 0.04%)  0.01% - 0.28%  2 (2, 0.08%)  0.02% - 0.31%  
SUTURE RELATED COMPLICATION  1 (1, 0.04%)  0.01% - 0.28%  2 (2, 0.08%)  0.02% - 0.31%  
SWELLING  0 (0, 0%)  -- 2 (2, 0.08%)  0.02% - 0.33%  
SWELLING  0 (0, 0%)  -- 2 (2, 0.08%)  0.02%  - 0.33%  
SYNCOPE  4 (4, 0.15%)  0.06% - 0.40%  5 (5, 0.20%)  0.08% - 0.47%  
SYNCOPE  4 (4, 0.15%)  0.06% - 0.40%  5 (5, 0.20%)  0.08% - 0.47%  
THROMBOPHLEBITIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
THROMBOPHLEBITIS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
THROMBOSIS  2 (2, 0.08%)  0.02% - 0.31%  4 (4, 0.18%)  0.07% - 0.47%  
THROMBOSIS  2 (2, 0.08%)  0.02% - 0.31%  4 (4, 0.18%)  0.07% - 0.47%  
TRANSIENT ISCHAEMIC ATTACK  2 (2, 0.08%)  0.02% - 0.30%  2 (2, 0.08%)  0.02% - 0.30%  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 80 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 16: Previous Clinical Study Data - System and/or Procedure Related Adverse Events  (n=2667)  
 Within [ADDRESS_567366] Level Term  No. Events  
(No. Subjects, 
%)1 95% CI1 No. Events  
(No. Subjects, 
%)1 95% CI1 
TRANSIENT ISCHAEMIC ATTACK  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
TRANSIENT ISCHEMIC ATTACKS  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
UNDERSENSING  9 (9, 0.34%)  0.18% - 0.65%  13 (13, 0.53%)  0.31% - 0.92%  
LOSS OF SENSING  2 (2, 0.07%)  0.02% - 0.30%  3 (3, 0.11%)  0.04% - 0.35%  
UNDERSENSING  7 (7, 0.27%)  0.13% - 0.56%  10 (10, 0.42%)  0.22% - 0.78%  
VASCULAR PSEUDOANEURYSM  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
VASCULAR PSEUDOANEURYSM  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
VENOUS INSUFFICIENCY  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
VENOUS EDEMA  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
VENOUS THROMBOSIS  8 (8, 0.31%)  0.15% - 0.61%  8 (8, 0.31%)  0.15% - 0.61%  
VENOUS THROMBOSIS  8 (8, 0.31%)  0.15% - 0.61%  8 (8, 0.31%)  0.15% - 0.61%  
VENTRICULAR EXTRASYSTOLES  10 (10, 0.38%)  0.21% - 0.71%  11 (11, 0.42%)  0.23% - 0.76%  
FUSION BEAT  0 (0, 0%)  -- 1 (1, 0.04%)  0.01% - 0.28%  
PREMATURE VENTRICULAR CONTRACTIONS  10 (10, 0.38%)  0.21% - 0.71%  10 (10, 0.38%)  0.21% - 0.71%  
VENTRICULAR TACHYCARDIA  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
VENTRICULAR TACHYCARDIA  2 (2, 0.08%)  0.02% - 0.31%  2 (2, 0.08%)  0.02% - 0.31%  
VIRAL INFECTION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
VIRAL INFECTION  1 (1, 0.04%)  0.01% - 0.27%  1 (1, 0.04%)  0.01% - 0.27%  
 
APPENDIX D: PARTICIPATING INVESTIGATORS AND INSTITUTIONS  
 A complete list of participating investigators and institutions (including names, titles/professional 
positions, address(es), and telephone numbers) where study activities will be conducted will be provided 
upon request under a separate cover .  
 
APPENDIX E: ETHICS COMMITTEE  (IRB)  
 A complete list of participating IRB and the Chairperson(s) will be distributed under separate cover when 
available upon request.  
 
APPENDIX F: LABELING  
Labeling and packaging for all products used in this study will follow the local regulatory requirements. 
Labeling for all system components market released at study start in the respective geographies can be 
found with each package insert and/or will be available on http://manuals.medtronic.com . In the event a 
non-Medtronic lead is used, governing labeling for that lead should be consulted.  
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 81 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 APPENDIX G: CIP Change History  
Table 17: Change History  CIP V1.0 to CIP V2.0  
Applicable  Sections  Change  Rationale  
Title Page, Appendix D & E , 
header/footer  Update  to Version  2.[ADDRESS_567367] Information  Clinical  Study  Leader  now 
Andrea De[COMPANY_002],  
previously  Scott Sarazin  Role change  
CROs/Core Laboratories  Added The Ohio State 
University as the 
echocardiographu core lab 
and ACM Glabal Central 
Lanoratory as the blood core 
lab Formally  adding contact 
[CONTACT_446172]  
1. Version History  Added  version 2.0  CIP Update  
4. Synopsis  Removed “Ensura MRI” in 
the Product Name [CONTACT_446181]  
4. Synopsis ; Exclusion  Criteria , 
9.4  Changed criteria from “Subject 
has permanent AF or AF at 
time of enrollment visit” to 
Subject has permanent AF or 
AF noted on baseline 
interrogation rhythm strip”  Provide clairi fcation to criteria  
4. Synopsis; Exclusion  Criteria, 
9.4 Added “ prior to enrollment” 
for exclusion criteria regarding 
aortic valve replacement 
procedure less than 1  year  Provide clairifcation to criteria  
4. Synopsis ; Exclusion Criteria , 
9.4 Added “Subject has 
know coronary disease  
with Class II angina”   Added per Steering Committee  
recommendation  
4. Synopsis ; Study Pro cedures 
and Assessments , 10.8  Added “Subject observation 
of at least [ADDRESS_567368] 
programming”  Added per Steering Committee 
recommendation  
4. Synopsis; Study Pro cedures 
and Assessments , 10.9  Added a 24 Hour Telephone 
call Follow -Up Visit Added per Steering Committee 
recommendation  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 82 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable  Sections  Change  Rationale  
7. Study Design  Removed “This study is a 
Non-Significant Risk (NSR) 
Investigational Device 
Examption (IDE) study as 
subjects will already have 
implanted market -approved 
Medtronic pacemakers that 
have the Sleep Function.” 
And added “ The REVAMP 
study will be conducted as a 
Non-Significant Risk (NSR) 
IDE study. The REVAMP 
Research System does not 
include an investigational 
device; the ability to program 
a lower rate of 100 bpm is 
available in market -released 
pacemakers, and the Sleep 
function (which allows a 
different rate to be 
programmed for part of a 24 
hour clock) is an approved 
feature in market -released 
pacemakers that will be used 
in the clinical stu dy. The 
study will be conducted in 
compliance with 21 CFR Parts 
11, 50, 56, 812 .2 (b)(1) . This 
study does not require an 
IDE submission to FDA. ” 
 Provide further clearity around 
the meaning of a Non -
Significant Risk IDE study  
7.1 Duration  Removed sentence  regarding 
study  start date  Not required  
8.3 Study Componets , 10.3   Added “Access to dry ice to 
ship blood samples”  Provide  clarity around shippi[INVESTIGATOR_446138]  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 83 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable  Sections  Change  Rationale  
10. Study Procedures  Added the following “ At the 
request  of the Principal 
Investigator [INVESTIGATOR_446139], 
Medtronic will use 
information from its device 
registration database to 
provide a study site a list of 
its patients whom the site 
had implanted with the 
Medtronic dual chamber 
pacemaker wit h Sleep 
Function, required by [CONTACT_446173] 9.3.  Study site, if 
permitted by [CONTACT_286032], could 
further review the records of 
such patients to determine if 
they may be eligible to 
participate in the study.”  To allow Medtronic access to 
potential study subjects at the 
study site using device 
database  
10.[ADDRESS_567369] programming  Added per Steering Committee 
recommendation  
10.5 Prior and Concomitant 
Medications  Added “all telephone call 
follow up visits” to the second 
sentence in the paragraph  To be consistant with schedule 
of events table  
10.8 Baseline Visit  Added “In the event a subject 
experiences symptoms once 
sent home after the Baseline 
visit, the subject should be 
instructd to seek medical help 
for device repro gramming if 
they cannot or do not 
tolerate elevated pacing.”  Added per Steering Committee 
recommendation  
10.10.1 Blinding  Added “Refer to the 
Randomization and Blinding 
Plan for specific details.”  Provide further clearity as to 
where to find this detailed 
information  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 84 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable  Sections  Change  Rationale  
10.12 unscheduled Follow -Up 
Visits Changed “An unscheduled 
visit is defined as a visit not 
required by [CONTACT_446174].” To now 
read “An unscheduled visit is 
defined as any unplanned 
visit by [CONTACT_446175]. Routine visits or 
other planned visits are n ot 
collected.”  Provide clearity for how this 
visit is defined  
10.13 12 Week Visit (Study 
Exit) Added “NYHA” as a bullet  To be consistant with schedule 
of events table  
15.1 Statement(s) of 
Compliance  Added the following sentence 
“ The study was designed to 
reflect the GCP principles 
outlined in ICO [ZIP_CODE]:2011.”  Required per Medtroinc CIP 
checklist  
16.1 Monitoring  Changed “Monitoring for the 
study, including site initiation 
visits, interim monitoring 
visits, and closeout visits, will 
be done in accordance  to the 
study -specific plan.” To now 
read “Monitoring for the study 
will be done in accordance to 
the study -specific plan  Specific details to be outlined in 
the Monitoring Plan  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 85 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable  Sections  Change  Rationale  
16.2 Data Management  Revised this paragraph from 
“Procedures in the CIP require 
source documentation.  Source 
documentation will be 
maintained at the site. Source 
documents, which may include 
worksheets, patient medical 
records, echo data, 
programmer printouts, device 
interrogation files, must be 
created and maintained by [CONTACT_446159].” To 
“Procedures in the CIP require 
source documentation.  Source 
documentation will be 
maintained at the site. Source 
may include worksheets, patient 
medical records, echo data, 
programmer pr intouts, device 
interrogation files, and certain 
CRF fields which must be 
created and maintained by [CONTACT_446159].”   
  
 Provide clearity that only certain 
CRF fields will need source 
documents created  
 
  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 86 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Table 18: Change History CIP V2.0 to CIP V3.0  
Applicable Sections  Change  
DHQNT  Rationale  
1. Version History  Added Version 3.0  
Table 18  
 CIP Update  
 
 
1. Version History  Added Table 17 to V2.0  Clarification of changes  
 3.  Glossary  Added ADL (Activities of Daily 
Living) and UR (Upper Rate)  Consistency within protocol  
4.   Synopsis; Sample Size  Increased number of subjects 
from 40 to 50 and number of 
sites from approximately 5 sites 
to 10 sites  Recommended by [CONTACT_446176]  
4. Synopsis;  
Inclusion/Exclusion Criteria and 
9. Selection of Subjects  
    9.3. Inclusion Criteria  
  Changed Subject has had a 
marked released dual chamber 
Medtronic Pacemaker with 
Sleep Function for at [ADDRESS_567370] 3 months.  Change recommended by 
[CONTACT_385321]  
4.  Synopsis; 
Inclusion/Exclusion Criteria and  
9.  Selection of Subjects  
     9.3. Inclusion Criteria  Changed from Subject has 
dyspnea with exertion to 
Subject has dyspnea with 
exertion or diagnosed as NYHA 
Class II or III heart Failure  Clarification recommended by 
[CONTACT_385321]  
4.  Synopsis; 
Inclusion/Exclusion Criteria and  
9. Selection of Subjects  
   9.4. Exclusion Criteria  Changed from Subject has 
more than moderate valve 
disease to Subject has severe 
stenosis of the aortic or mitral 
valve, defined as a valve area 
less than or equal to 1.0cm² or 
subject has severe 
regurgitation of the aortic or 
mitral valve.  Clarification recommended by 
[CONTACT_385321]  
 
 
 
 
 
 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 87 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable Sections  Change  
DHQNT  Rationale  
4.  Synopsis; 
Inclusion/Exclusion Criteria  
9. Selection of Subjects  
   9.4. Exclusion Criteria  Changed from Subject has had 
an aortic valve replacement 
(surgical or TAVR) procedure 
less than [ADDRESS_567371] has 
had an aortic valve 
replacement (surgical or TAVR) 
procedure less than [ADDRESS_567372] of analyses  Removal of redundant 
information; can see in Section 
14.1 Endpoint Definitions  
14.1 Endpoint Definitions  
14.1.2 . Ancillary Safety 
Endpoint – NT-proBNP, 
troponin, LVEF  
14.1.4 . Ancillary Efficacy 
Endpoint – Quality of Life  
14.1.5 . Ancillary Efficacy 
Endpoint – Mobility and Activity  
14.1.6 . Ancillary Efficacy 
Endpoint – Echo Measurements  
14.1.7 . Ancillary Efficacy 
Endpoint – Collagen Degration 
Biomarker Measurements  Updated symbols to show µ 
instead of a square  Consistency within protocol  
14.1.4 . Ancillary Efficacy 
Endpoint – Quality of Life  Added EQ -5D-5L Questionnaire 
– 8 weeks section  Clarify the quality of life 
analyses  
14.1.5 . Ancillary Efficacy 
Endpoint – Mobility and Activity  Updated ‘:’ to ‘ -‘ in section 
header; Updated MNLWHF for 
week [ADDRESS_567373] distance  Consistency within protocol  
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 88 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 Applicable Sections  Change  
DHQNT  Rationale  
14.1.7 . Ancillary Efficacy 
Endpoint – Collagen 
Degradation Biomarker 
Measurements   Updated echo to collagen 
degration biomarker at week 8  Consistency within protocol  
10.  Study Procedure  
10.2. Rose of Sponsor 
Representative   
 Added to specify MDT field role  Clarify MDT field role  
Appendix G:  CIP Change  
Table [ADDRESS_567374]  
Sponsor’s Medical Expert  [INVESTIGATOR_446178] 18  
CIP Changes V2 to V3  Capture changes in CIP  
Appendix G:  CIP Change  
Added Table 18  
CIP Changes V2 to V3  Addition of Table of Changes  Capture changes V2 to V3  
Throughout CIP  Formatting & grammatical  
changes  Format change & grammatical 
errors  
Table 15: Sponsor Reports for 
the [LOCATION_002]  Removed:  
Recall and Disposition  
Other  
 Not required for NSR IDE  
APPENDIX D:  Participating 
Investigators and Institutions  
APPENDIX E:  Ethics Committee 
(IRB)  Removed : 
 At the time of REVAMP CIP V2 
completion were not finalized  Site selections have been made 
for 5 sites  since V2  
10: Study Procedure  
10.9.1.   Programming 
Recommendations at Baseline  
 Added:  Use of AAI (R) 
programming is not 
recommended due to the 
possibility of AV block occurring 
at higher rate pacing.    Clarifying Programming 
recommendation  
  
056-F275, Clinical Inves tigation Plan Template, Version 2.[ADDRESS_567375] of heart failure in the [LOCATION_002]: a policy 
statement from the American Heart Association.  Circ Heart Fail, 2013. 6(3): p. 606 -19. 
2. Owan, T.E., et al., Trends in prevalence and outcome of heart failure with preserved ejection 
fraction.  N Engl J Med, 2006. 355(3): p. 251 -9. 
3. Katz, D.H., et al., Prevalence, clinical characteristics, and outcomes associated with eccentric 
versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.  Am 
J Cardiol, 2013. 112(8): p. 1158 -64. 
4. Borlaug, B.A., The pathophysiology of heart failure with preserved ejection fraction.  Nat Rev 
Cardiol, 2014. 11(9): p. [ADDRESS_567376] human left 
ventricular hypertrophy. Systo lic versus diastolic determinants.  Circulation, 1993. 88(4 Pt 1): p. 
1893-906. 
6. Tomita, M., et al., Changes in left ventricular volume, mass, and function during the development 
and regression of supraventricular tachycardia -induced cardiomyopathy. Dispa rity between 
recovery of systolic versus diastolic function.  Circulation, 1991. 83(2): p. 635 -44. 
7. Klein, F.J., et al., Heart -Rate Induced Modifications of Concentric Left Ventricular Hypertrophy  - 
Exploration of a Novel Therapeutic Concept . AM J Physiology, Published 2 September 2016 Vol. 
no. , DOI: 10.1152/ajpheart.[ZIP_CODE].2016 . 
8. Spi[INVESTIGATOR_7992], F.G., et al., Relation between ventricular and myocyte remodeling with the development 
and regression of supraventricular tachycardia -induced cardiomyopat hy. Circ Res, 1991. 69(4): 
p. 1058 -67. 
9. Medi, C., et al., Tachycardia -mediated cardiomyopathy secondary to focal atrial tachycardia: 
long-term outcome after catheter ablation.  J Am Coll Cardiol, 2009. 53(19): p. [ADDRESS_567377] MRI Sures can A2DR01, Advisa SR MRI Surescan A3SR01 Clinician Manual.  
2015(M961530A001 B): p. 358.  
11. Yamanaka, T., et al., Force - and relaxation -frequency relations in patients with diastolic heart 
failure.  Am Heart J, 2006. 152(5): p. 966 e1 -7. 
12. Westermann, D. , et al., Role of left ventricular stiffness in heart failure with normal ejection 
fraction.  Circulation, 2008. 117(16): p. 2051 -60. 
13. Inagaki, M., et al., Impaired force -frequency relations in patients with hypertensive left 
ventricular hypertrophy. A p ossible physiological marker of the transition from physiological to 
pathological hypertrophy.  Circulation, 1999. 99(14): p. 1822 -30. 
14. Spi[INVESTIGATOR_7992], F.G., et al., Time-dependent changes in matrix metalloproteinase activity and expression 
during the progressi on of congestive heart failure: relation to ventricular and myocyte function.  
Circ Res, 1998. 82(4): p. 482 -95. 
15. Ahmed, S.H., et al., Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship 
between changes in proteolytic determin ants of matrix composition and structural, functional, 
and clinical manifestations of hypertensive heart disease.  Circulation, 2006. 113(17): p. 2089 -96. 
16. Meijers, W.C., A.R. van der Velde, and R.A. de Boer, Biomarkers in heart failure with preserved 
ejection fraction.  Neth Heart J, 2016. 24(4): p. 252 -8. 
17. Ponikowski, P., et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure 
of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart 
Failure Association (HFA) of the ESC.  Eur J Heart Fail, 2016. 18(8): p. 891 -975. 
056-F275, Clinical Inves tigation Plan Template, Version 2.0  Page 90 of 90 
Version 3.0  REVAMP Clinical Investigation Plan   
27 APR 2018  Medtronic Confidential  
 18. Roberts, E., et al., The diagnostic accuracy of the natriuretic peptides in h eart failure: systematic 
review and diagnostic meta -analysis in the acute care setting.  BMJ, 2015. 350: p. h910.  
19. Peacock, W.F ., et al., Cardiac Troponin and outcome in actue heart failure . New England J Med, 
2008. 358: p. 2 117-26. 
20. Meijers, W.C., et  al., Patients with heart failure with preserved ejection fraction and low levels of 
natriuretic peptides.   Neth Heart J, 2016.  24: p. 287 -95. 
21. Macin, S.M., et al., Increased levels of cardiac troponin -T in outpatients with heart failure and 
preserved systolic function are related to adverse clinical findings and outcome.  Coron Artery 
Dis, 2006. 17: p. 685 -91. 
22. Shah, AM, et al., Cardiac structure and function a nd prognosis in heart failure with preserved 
ejection fraction: findings from the echocardiographic study of the Treatment of Preserved 
Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.  Circ Heart Fail  7, 
2014. p. 740–751. 
 